[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2184
1. Anderson CA, Curzon ME, Van Loveren C, Tatsi C, Duggal MS: Sucrose and dental caries: a review of the evidence. Obes Rev; 2009 Mar;10 Suppl 1:41-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sucrose and dental caries: a review of the evidence.
  • The aim of this study was to conduct a review of the literature to assess the relationship between quantity and pattern of sucrose use and dental caries.
  • Using hand and electronic methods (MEDLINE, EMBASE) the literature was searched for epidemiological papers concerning any relationship of sugars and dental caries published since 1856.
  • Superficial hand searching was carried out between 1856 and 1940, detailed hand searching 1940-1966 and electronic 1966-2007.
  • Selection criteria were set based on, but not confined to, Cochran style standards.
  • Investigations were categorized as A, fulfilling all criteria; B1, relevant fulfilling 19 of 23 criteria; B2, relevant but fulfilling only between 12 and 18 of the selection criteria; and C, all other papers.
  • There were 95 papers meeting most (more than 12) or all of the selected criteria.
  • Only 1 paper was graded A; 31 as B1.
  • There were in addition some 65 as B2 and all the rest as C, which were discarded.
  • There were a wide variety of study designs and those graded A or B1 comprised 23 ecological cross-sectional, 7 cohort and 2 case control studies.
  • Summary results showed that 6 papers found a positive, significant relationship of sugar quantity to dental caries, 19 of 31 studies reported a significant relationship of sugar frequency of use to dental caries.
  • The balance of studies does not demonstrate a relationship between sugar quantity, but a moderately significant relationship of sugar frequency to dental caries.
  • [MeSH-major] Dental Caries / etiology. Dietary Sucrose / adverse effects
  • [MeSH-minor] Humans

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207535.001).
  • [ISSN] 1467-789X
  • [Journal-full-title] Obesity reviews : an official journal of the International Association for the Study of Obesity
  • [ISO-abbreviation] Obes Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Sucrose
  • [Number-of-references] 44
  •  go-up   go-down


2. Wang SD, Yuan L, Jiang Y, Li XQ, Wang XZ: [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement]. Zhonghua Yi Xue Za Zhi; 2007 Sep 4;87(33):2316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement].
  • OBJECTIVE: To investigate the myocardial protective effect of Shenfu injection in patients undergoing valve replacement.
  • METHODS: Forty patients undergoing valve replacement surgery under cardio-pulmonary bypass (CPB) were randomly divided into two equal groups: group C (control group, given with 4:1 blood containing cardioplegic liquid during the CPB) and group SF (Shenfu injection, receiving the blood containing cardioplegic liquid with 20 ml/L of Shenfu injection additionally).
  • Blood samples were withdrawn from the central vein before operation, 30 minutes after aorta declamping, and 4, 12, and 24 hours after CPB, to test the serum cardiac troponin I (cTnI), creatine phosphokinase (CK), and creatine phosphokinase isoenzyme (CK-MB).
  • RESULTS: The CK, CK-MB, and cTnI level were normal before operation and there were no significant differences in these indexes between the two groups.
  • 30 minutes after aorta declamping, the CK, CK-MB, and cTnI levels were higher than those before operation in both groups (P < 0.05, P < 0.
  • 01), and the higher levels remained to 24 hours after CPB.
  • 24 hours after CPB, the CK level of the group SF was significantly lower than that of the group C (P < 0.05), and 30 minutes after aorta declamping to 24 h after CPB, the CK-MB and cTnI levels were lower in the group SF compared with the group C (all P < 0. 05).
  • CONCLUSION: Shenfu injection decreases the level of CK, CK-MB and cTnI, and reduces the myocardial injury.
  • [MeSH-major] Cardiomyopathies / prevention & control. Drugs, Chinese Herbal / therapeutic use. Heart Valve Prosthesis Implantation / methods
  • [MeSH-minor] Adult. Aged. Cardioplegic Solutions / administration & dosage. Cardiopulmonary Bypass. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Creatine Kinase / blood. Creatine Kinase, MB Form / blood. Female. Heart Arrest, Induced / methods. Humans. Male. Middle Aged. Troponin I / blood

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036292.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cardioplegic Solutions; 0 / Cardiotonic Agents; 0 / Drugs, Chinese Herbal; 0 / Shen-Fu; 0 / Troponin I; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, MB Form
  •  go-up   go-down


3. Bashashati A, Nouredin B, Ward RK, Lawrence P, Birch GE: Effect of eye-blinks on a self-paced brain interface design. Clin Neurophysiol; 2007 Jul;118(7):1639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of eye-blinks on a self-paced brain interface design.
  • OBJECTIVE: To test the performance of an EEG-based self-paced brain interface when data contaminated with eye-blink artefacts are included in the evaluation.
  • METHODS: Two different designs of a self-paced brain interface (the low frequency-asynchronous switch design, LF-ASD) are evaluated and compared using offline data from eight subjects.
  • The true positive rates of the two designs are compared for three cases: (a) data containing eye-blink artefacts are excluded from the input;.
  • (b) all data, including eye-blinks, are included as input but the output decisions are inactivated during eye-blink artefacts;.
  • (c) all the data, including eye-blinks, are included as input and the output decisions are reported in all times including during eye-blink artefacts.
  • RESULTS: The true positive rates of one design of the LF-ASD (LF-ASD-V5) for case (c) and of another design (LF-ASD-V4) for case (b) are 40.5% and 42.4%, respectively, for false positive rates of 1%.
  • CONCLUSIONS: The true positive rates of LF-ASD-V5 when eye-blinks are included in the analysis deteriorate slightly compared to when the output during eye-blink artefacts is inactivated in LF-ASD-V4.
  • SIGNIFICANCE: LF-ASD-V5 allows the device to be functional at all times and can handle artefacts better than LF-ASD-V4.
  • If a slight decrease in true positive rates is acceptable, no further devices are needed to record the electro-oculogram (EOG) for detecting eye-blinks.
  • [MeSH-major] Artifacts. Blinking / physiology. Brain / physiology. Electroencephalography / instrumentation
  • [MeSH-minor] Adult. Data Interpretation, Statistical. Electrooculography. False Positive Reactions. Female. Fingers / physiology. Humans. Male. Middle Aged. Movement / physiology. ROC Curve. Spinal Cord Injuries / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466588.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Tommasi F, Paciolla C, de Pinto MC, De Gara L: Effects of storage temperature on viability, germination and antioxidant metabolism in Ginkgo biloba L. seeds. Plant Physiol Biochem; 2006 May-Jun;44(5-6):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 25 degrees C a significant decrease in the ASC content in the embryos was evident, whereas it remained more stable in the endosperm.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889978.001).
  • [ISSN] 0981-9428
  • [Journal-full-title] Plant physiology and biochemistry : PPB
  • [ISO-abbreviation] Plant Physiol. Biochem.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.- / Oxidoreductases; EC 1.11.1.- / Peroxidases; EC 1.11.1.11 / Ascorbate Peroxidases; EC 1.11.1.6 / Catalase; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.5.4 / monodehydroascorbate reductase (NADH); EC 1.8.1.7 / Glutathione Reductase; EC 1.8.5.1 / glutathione dehydrogenase (ascorbate); GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


5. Troughton RW, Richards AM: Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement. Am J Cardiol; 2008 Feb 4;101(3A):72-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement.
  • Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong and independent prognostic marker in patients across the spectrum of heart failure (HF) stages, including patients managed in the outpatient setting.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243863.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 37
  •  go-up   go-down


6. Inukai T, Zhang X, Kameyama T, Suzuki Y, Yoshikawa K, Kuroda I, Nemoto A, Akahane K, Sato H, Goi K, Nakamoto K, Hamada J, Tada M, Moriuchi T, Sugita K: A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines. Am J Hematol; 2010 Jul;85(7):535-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
  • [MeSH-major] Mutation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. Oncogene Proteins, Fusion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575032.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimarães H, Areias JC, Correia-Pinto J: N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology; 2008;94(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants.
  • Plasmatic N-terminal-pro-B type natriuretic peptide (NT-proBNP) might be useful in diagnosis and management of PH in newborns, although its interest in CDH infants remains to be defined.
  • [MeSH-major] Heart / physiopathology. Hernia, Diaphragmatic / physiopathology. Hernias, Diaphragmatic, Congenital. Hypertension, Pulmonary / blood. Hypertension, Pulmonary / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18160811.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


8. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM: Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol; 2006 Aug 15;98(4):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
  • The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC.
  • Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing.
  • The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001).
  • NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012).
  • There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003).
  • On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max.
  • A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%.
  • In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893708.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


9. Thummes K, Schäfer J, Kämpfer P, Jäckel U: Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments. Syst Appl Microbiol; 2007 Dec;30(8):634-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments.
  • Since compost is widely used as soil amendment and the fact that during the processing of compost material high amounts of microorganisms are released into the air, we investigated whether compost may act as a carrier for thermophilic methanogens to temperate soils.
  • All eight investigated compost materials showed a clear methane production potential between 0.01 and 0.98 micromol CH(4) g dw(-1)h(-1) at 50 degrees C.
  • Single strand conformation polymorphism (SSCP) and cloning analysis indicated the presence of Methanosarcina thermophila, Methanoculleus thermophilus, and Methanobacterium formicicum.
  • Bioaerosols collected during the turning of a compost pile showed both a highly similar SSCP profile compared to the corresponding compost material and clear methane production during anoxic incubation in selective medium at 50 degrees C.
  • Both observations indicated a considerable release of thermophilic methanogens into the air.
  • To analyse the persistence of compost-borne thermophilic methanogens in temperate oxic soils, we therefore studied their potential activity in compost and compost/soil mixtures, which was brought to a meadow soil, as well as in an agricultural soil fertilised with compost.
  • After 24h anoxic incubation at 50 degrees C, all samples containing compost showed a clear methanogenic activity, even 1 year after application.
  • In combination with the in vitro observed resilience of the compost-borne methanogens against desiccation and UV radiation we assume that compost material acts as an effective carrier for the distribution of thermophilic methanogens by fertilisation and wind.
  • [MeSH-major] Methane / biosynthesis. Methanobacterium / isolation & purification. Methanomicrobiaceae / isolation & purification. Methanosarcina / isolation & purification. Soil Microbiology
  • [MeSH-minor] DNA, Bacterial / genetics. Desiccation. Hot Temperature. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Ultraviolet Rays

  • Hazardous Substances Data Bank. METHANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988815.001).
  • [ISSN] 0723-2020
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AM747292/ AM747293/ AM747294/ AM747295/ AM747296/ AM747297/ AM747298/ AM747299/ AM747300/ AM747301
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; OP0UW79H66 / Methane
  •  go-up   go-down


10. Victor S, Marson AG, Appleton RE, Beirne M, Weindling AM: Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants. Pediatr Res; 2006 Feb;59(2):314-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants.
  • There is uncertainty about the level of systemic blood pressure required to maintain adequate cerebral oxygen delivery and organ integrity.
  • This prospective, observational study on 35 very low birth weight infants aimed to determine the mean blood pressure (MBP) below which cerebral electrical activity, peripheral blood flow (PBF), and cerebral fractional oxygen extraction (CFOE) are abnormal.
  • Digital EEG, recorded every day on the first 4 d after birth, were analyzed a) by automatic spectral analysis, b) by manual measurement of interburst interval, and c) qualitatively.
  • CFOE and PBF measurements were performed using near-infrared spectroscopy and venous occlusion.
  • MBP was measured using arterial catheters.
  • The median (range) of MBP recorded was 32 mm Hg (16-46).
  • The EEG became abnormal at MBP levels below 23 mm Hg: a) the relative power of the delta (0.5-3.5 Hz) frequency band was decreased, b) interburst intervals were prolonged, and c) all four qualitatively abnormal EEG (low amplitude and prolonged interburst intervals) from four different patients were recorded below this MBP level.
  • The only abnormally high CFOE was measured at MBP of 20 mm Hg.
  • PBF decreased at MBP levels between 23 and 33 mm Hg.
  • None of the infants in this study developed cystic periventricular leukomalacia.
  • One infant (MBP, 22 mm Hg) developed ventricular dilatation after intraventricular hemorrhage.
  • The EEG and CFOE remained normal at MBP levels above 23 mm Hg.
  • It would appear that cerebral perfusion is probably maintained at MBP levels above 23 mm Hg.
  • [MeSH-major] Blood Pressure. Brain / physiology. Cerebrovascular Circulation. Infant, Very Low Birth Weight / physiology. Oxygen / metabolism
  • [MeSH-minor] Electroencephalography. Fourier Analysis. Humans. Infant, Newborn

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439599.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


11. Szczepanek J, Pogorzala M, Konatkowska B, Juraszewska E, Badowska W, Olejnik I, Kuzmicz M, Stanczak E, Malinowska I, Stefaniak J, Sobol G, Szczepanski T, Czyzewski K, Wysocki M, Styczynski J: Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res; 2010 Jun;30(6):2119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
  • The objective of this study was the analysis of the ex vivo activity of bortezomib in paediatric acute lymphoblastic leukaemia (ALL), in comparison to paediatric acute myeloid leukaemia (AML).
  • A total of 159 patients entered the study, including 106 ALL (including 86 precursor-B-cell ALL, and 20 T-cell ALL) and 53 AML children.
  • With respect to immunophenotype, ex vivo drug resistance in T-cell ALL (T-ALL) was higher for most of the drugs.
  • No differences in drug resistance between T-ALL and common/pre-B-cell-ALL were found for daunorubicin, mitoxantrone and 6-thioguanine.
  • Bortezomib was the only compound which was more active in T-ALL than in common/pre-B-ALL paediatric samples.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651360.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


12. Coleman CB, Nealy MS, Tibbetts SA: Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J Virol; 2010 Dec;84(24):13045-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gammaherpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 [HHV-8]), Epstein-Barr virus (EBV), and murine gammaherpesvirus 68 (MHV68; also known as gammaherpesvirus 68 [γHV68] or murine herpesvirus 4 [MuHV-4]), establish lifelong latency in the resting memory B cell compartment.
  • However, little is known about how this reservoir of infected mature B cells is maintained for the life of the host.
  • In the context of a normal immune system, the mature B cell pool is naturally maintained by the renewable populations of developing B cells that arise from hematopoiesis.
  • Thus, recurrent infection of these developing B cell populations could allow the virus continual access to the B cell lineage and, subsequent to differentiation, the memory B cell compartment.
  • In work described here, we demonstrate the presence of viral genome in bone marrow pro-pre-B cells and immature B cells during early latency and immature B cells during long-term latency.
  • Because developing B cells normally exhibit a short life span and a high rate of turnover, these findings suggest a model in which gammaherpesviruses may gain access to the mature B cell compartment by recurrent seeding of developing B cells.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Feb;74(3):1101-13 [10627520.001]
  • [Cites] J Virol. 2010 Aug;84(15):7523-34 [20484501.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):6834-40 [11739500.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] J Virol. 2002 Jul;76(14):7125-32 [12072512.001]
  • [Cites] J Virol. 2003 Feb;77(4):2522-9 [12551990.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3828-34 [12646650.001]
  • [Cites] J Virol. 2003 Jul;77(13):7308-18 [12805429.001]
  • [Cites] J Virol. 2003 Jul;77(13):7696-701 [12805472.001]
  • [Cites] Cancer. 1979 Sep;44(3):993-1002 [225008.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4262-79 [7030473.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):290-3 [6321323.001]
  • [Cites] Transplantation. 1985 May;39(5):461-72 [2986325.001]
  • [Cites] Blood. 1985 May;65(5):1097-104 [2986741.001]
  • [Cites] Blood. 1988 May;71(5):1234-43 [2833957.001]
  • [Cites] Blood. 1988 Aug;72(2):520-9 [2840986.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1988 Fall;10(3):196-205 [2845831.001]
  • [Cites] J Gen Virol. 1989 May;70 ( Pt 5):1203-15 [2543775.001]
  • [Cites] J Gen Virol. 1992 Sep;73 ( Pt 9):2347-56 [1328491.001]
  • [Cites] J Immunol. 1993 Nov 1;151(9):4431-44 [8409411.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3259-64 [8241498.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):704-11 [7772506.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 20;12(8):651-7 [8744575.001]
  • [Cites] J Virol. 1996 Oct;70(10):6775-80 [8794315.001]
  • [Cites] Immunity. 1996 Dec;5(6):527-35 [8986713.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):863-71 [9064346.001]
  • [Cites] Acta Haematol. 1997;98(1):32-6 [9210911.001]
  • [Cites] Science. 1998 Jan 2;279(5347):84-8 [9417030.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1074-7 [9781644.001]
  • [Cites] J Virol. 1999 Jun;73(6):4651-61 [10233924.001]
  • [Cites] J Exp Med. 1999 Jul 5;190(1):75-89 [10429672.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):613-6 [10504449.001]
  • [Cites] J Virol Methods. 2005 Jun;126(1-2):91-100 [15847924.001]
  • [Cites] Mod Pathol. 2006 May;19(5):726-37 [16528368.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):149-57 [18434123.001]
  • [Cites] J Virol. 2008 Sep;82(17):8500-8 [18562537.001]
  • [Cites] J Virol. 2009 Jul;83(13):6484-93 [19386718.001]
  • [Cites] PLoS One. 2009;4(8):e6492 [19652715.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1378-85 [11070102.001]
  • (PMID = 20926565.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR018724; United States / NCI NIH HHS / CA / R01 CA139984; United States / NCI NIH HHS / CA / CA139984; United States / NCRR NIH HHS / RR / P20-RR018724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC3004345
  •  go-up   go-down


13. Krejcí J, Harnicarová A, Kůrová J, Uhlírová R, Kozubek S, Legartová S, Hájek R, Bártová E: Nuclear organization of PML bodies in leukaemic and multiple myeloma cells. Leuk Res; 2008 Dec;32(12):1866-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nuclear arrangement of promyelocytic leukaemia nuclear bodies (PML NBs) was studied in vitro after the cell treatment by clinically used agents such as all-trans retinoic acid (RA) in human leukaemia and cytostatics or gamma radiation in multiple myeloma cells.
  • Studying the proteins involved in PML compartment, such as c-MYC, cell-type specific association of c-MYC and the PML NBs was observed in selected leukaemic cells undergoing differentiation, which was accompanied by c-MYC down-regulation.
  • [MeSH-major] Cell Cycle / physiology. Cell Nucleus / pathology. Intranuclear Inclusion Bodies / pathology. Leukemia, Promyelocytic, Acute / pathology. Multiple Myeloma / pathology
  • [MeSH-minor] Cell Differentiation / drug effects. Cell Line, Tumor. Flow Cytometry. Gamma Rays. HL-60 Cells / drug effects. HL-60 Cells / pathology. HL-60 Cells / radiation effects. Humans. K562 Cells / drug effects. K562 Cells / pathology. K562 Cells / radiation effects. Melphalan / pharmacology. Tetradecanoylphorbol Acetate / pharmacology. Tretinoin / pharmacology. U937 Cells / pathology


14. Lal R, Prasad DK, Krishna P, Sikora SS, Poddar U, Yachha SK, Kumari N: Biliary atresia with a "cyst at porta": management and outcome as per the cholangiographic anatomy. Pediatr Surg Int; 2007 Aug;23(8):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cholangiographic anatomy was classified as; Group A (n = 7), type III BA with extrahepatic cyst; Group B (n = 2), type I or II BA with extrahepatic biliary cyst; and Group C (n = 4), type I or II BA with both extrahepatic and intrahepatic biliary cysts.
  • The remaining 45 patients were comprised of type III BA without a cyst.
  • All 45 patients with type III BA without a cyst were treated by a Kasai's PE.
  • There were three early post-operative deaths, all in patients with type III BA without cyst.
  • Of the remaining 42 patients with type III BA without a cyst, 27 (64.3%) had bile flow, 13 (31%) became jaundice free and 14 (33.3%) have had 1-2 episodes of post-operative cholangitis.
  • The outcome was most satisfactory in type I BA without intrahepatic cystic dilatation (Group B) in terms of achieving a jaundice free state and freedom from recurrent cholangitis.
  • The outcome in type III BA with extrahepatic cyst was comparable to type III BA without cyst.

  • Genetic Alliance. consumer health - Biliary Atresia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):32-6 [2005521.001]
  • [Cites] J Pediatr Surg. 1994 May;29(5):630-4 [8035271.001]
  • [Cites] J Formos Med Assoc. 1996 Jul;95(7):567-71 [8840762.001]
  • [Cites] J Pediatr Surg. 1990 Oct;25(10):1076-80; discussion 1081 [2262862.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):997-1000 [12861525.001]
  • [Cites] Radiology. 1998 Nov;209(2):465-9 [9807575.001]
  • [Cites] Pediatr Surg Int. 2006 Oct;22(10):803-7 [16947025.001]
  • [Cites] Eur J Pediatr Surg. 1999 Oct;9(5):340-2 [10584198.001]
  • [Cites] Surgery. 1975 Mar;77(3):384-90 [1124494.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] J Pediatr Surg. 2006 Dec;41(12 ):1973-5 [17161184.001]
  • [Cites] AJR Am J Roentgenol. 1994 Jan;162(1):167-71 [8273658.001]
  • [Cites] J Pediatr Surg. 2000 Dec;35(12 ):1771-4 [11101734.001]
  • [Cites] J Pediatr Surg. 1998 May;33(5):700-4 [9607471.001]
  • [Cites] Eur J Pediatr Surg. 1998 Jun;8(3):146-9 [9676396.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 May;36(5):608-12 [12717083.001]
  • [Cites] Surgery. 1974 Feb;75(2):228-32 [4840842.001]
  • [Cites] J Pediatr Surg. 1987 Jun;22(6):522-5 [3612442.001]
  • [Cites] Semin Pediatr Surg. 2005 Feb;14(1):42-8 [15770587.001]
  • (PMID = 17569062.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, Persing DH: Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol; 2010 Oct;48(10):3719-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.
  • A total of 2,296 unformed stool specimens, collected from seven study sites, were tested by Xpert C. difficile enrichment culture followed by cell culture cytotoxicity testing of the isolates (i.e., toxigenic culture with enrichment) and the study sites' standard C. difficile test methods.
  • All C. difficile strains were typed by PCR-ribotyping.
  • The Xpert C. difficile assay is a simple, rapid, and accurate method for detection of toxigenic C. difficile in unformed stool specimens and is minimally affected by strain type compared to EIA and GDH-based methods.
  • [MeSH-major] Bacteriological Techniques / methods. Clostridium Infections / diagnosis. Clostridium difficile / isolation & purification. Molecular Diagnostic Techniques / methods

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1645-51 [10572152.001]
  • [Cites] J Hosp Infect. 2009 Jun;72(2):111-8 [19386381.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4031-7 [12958221.001]
  • [Cites] J Clin Microbiol. 1986 Mar;23(3):622-3 [3082928.001]
  • [Cites] J Clin Microbiol. 1991 Nov;29(11):2639-42 [1774279.001]
  • [Cites] J Clin Microbiol. 1993 Mar;31(3):507-11 [8458943.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):1145-9 [16517916.001]
  • [Cites] Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18 [16965399.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1152-60 [17918076.001]
  • [Cites] Clin Microbiol Infect. 2007 Nov;13(11):1048-57 [17850341.001]
  • [Cites] Clin Infect Dis. 2007 Nov 15;45(10):1266-73 [17968819.001]
  • [Cites] J Clin Microbiol. 2007 Nov;45(11):3601-5 [17804652.001]
  • [Cites] Euro Surveill. 2007 Jun;12(6):E1-2 [17991399.001]
  • [Cites] Infect Control Hosp Epidemiol. 2008 Mar;29(3):197-202 [18241032.001]
  • [Cites] J Clin Microbiol. 2008 Apr;46(4):1523-5 [18256226.001]
  • [Cites] J Clin Microbiol. 2008 Jun;46(6):1996-2001 [18434563.001]
  • [Cites] N Engl J Med. 2008 Oct 30;359(18):1932-40 [18971494.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3833-5 [18784313.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3686-9 [18845820.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):373-8 [19073875.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):176-9 [19652187.001]
  • [Cites] J Clin Microbiol. 2009 Sep;47(9):3004-7 [19571021.001]
  • [Cites] J Clin Microbiol. 2009 Oct;47(10):3211-7 [19710274.001]
  • [Cites] J Clin Microbiol. 2009 Nov;47(11):3729-31 [19741082.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):270-3 [19853666.001]
  • [Cites] J Clin Microbiol. 2009 Dec;47(12):3846-50 [19846637.001]
  • [Cites] J Clin Microbiol. 2010 Jan;48(1):124-30 [19923482.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Feb;66(2):129-34 [20117349.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):603-5 [19955275.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):606-8 [20032256.001]
  • [Cites] J Clin Microbiol. 2010 Mar;48(3):889-93 [20071552.001]
  • [Cites] Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72 [19215193.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Nov;23(11):639-40 [12452289.001]
  • (PMID = 20702676.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953097
  •  go-up   go-down


16. Hildebrandt P, Richards AM: Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol; 2008 Feb 4;101(3A):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension.
  • Although the current value of amino-terminal pro-B-type natriuretic peptides (NT-proBNP) to generally screen populations of "apparently well patients" remains promising but still undefined, the use of NT-proBNP to screen patients at high risk for heart disease (such as elderly patients, or patients with diabetes mellitus, hypertension, or known coronary artery disease) appears logical and is supported by data.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243853.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 19
  •  go-up   go-down


17. Ma X, Buffler PA, Wiemels JL, Selvin S, Metayer C, Loh M, Does MB, Wiencke JK: Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):1928-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia.
  • A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).
  • We evaluated the possible etiologic role of daycare attendance (a proxy measure for exposure to infectious agents) and infections during infancy in the Northern California Childhood Leukemia Study.
  • The magnitude of effect associated with the same number of child-hours was stronger for daycare attendance during infancy than for daycare attendance before diagnosis.
  • [MeSH-major] Child Day Care Centers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Child Care.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103439.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Zhang Y, Wang Y, Huang L, Chen D, Tao Y, Yuan Z: Effects of cooking and storage on residues of cyadox in chicken muscle. J Agric Food Chem; 2005 Dec 14;53(25):9737-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat stabilities of cyadox (CYX) and its two metabolites, 1,4-bisdesoxycyadox (BDCYX) and quinoxaline-2-carboxylic acid (QCA), in water, cooking oil, and as incurred residues in chicken muscle were investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332123.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinoxalines; 65884-46-0 / cyadox
  •  go-up   go-down


19. Airoldi I, Cocco C, Di Carlo E, Disarò S, Ognio E, Basso G, Pistoia V: Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res; 2006 Apr 15;66(8):3978-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.
  • The aim of this study was to investigate (i) whether the IL-12Rbeta2 gene is silenced in B-cell acute lymphoblastic leukemia (B-ALL) cells, and (ii) what the functional implications of such silencing for tumor growth are.
  • Here, we show that although mature B cells expressed both chains of the IL-12R, normal pro-B and pre-B cells failed to express the IL-12Rbeta2 chain.
  • Similarly, primary tumor cells from pediatric pro-B, early pre-B, and pre-B ALL (30 cases) did not express the IL-12Rbeta2 chain.
  • Such methylation was not detected in normal early B cells that when differentiated into mature B cells expressed the IL-12Rbeta2 gene.
  • Detection of IL-12Rbeta2 mRNA and protein in the tumorigenic 697 pre-B-ALL cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12).
  • [MeSH-major] Burkitt Lymphoma / genetics. DNA Methylation. Receptors, Interleukin / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / IL12RB2 protein, human; 0 / Il12rb2 protein, mouse; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-12
  •  go-up   go-down


20. van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Révész T, Staal FJ, van Dongen JJ: Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol; 2005 Nov 1;175(9):5912-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression.
  • The role of specific transcription factors in the initiation and regulation of Ig gene rearrangements has been studied extensively in mouse models, but data on normal human precursor B cell differentiation are limited.
  • We purified five human precursor B cell subsets, and assessed and quantified their IGH, IGK, and IGL gene rearrangement patterns and gene expression profiles.
  • Pro-B cells already massively initiate D(H)-J(H) rearrangements, which are completed with V(H)-DJ(H) rearrangements in pre-B-I cells.
  • Large cycling pre-B-II cells are selected for in-frame IGH gene rearrangements.
  • The first IGK/IGL gene rearrangements were initiated in pre-B-I cells, but their frequency increased enormously in small pre-B-II cells, and in-frame selection was found in immature B cells.
  • Transcripts of the RAG1 and RAG2 genes and earlier defined transcription factors, such as E2A, early B cell factor, E2-2, PAX5, and IRF4, were specifically up-regulated at stages undergoing Ig gene rearrangements.
  • Based on the combined Ig gene rearrangement status and gene expression profiles of consecutive precursor B cell subsets, we identified 16 candidate genes involved in initiation and/or regulation of Ig gene rearrangements.
  • These analyses provide new insights into early human precursor B cell differentiation steps and represent an excellent template for studies on oncogenic transformation in precursor B acute lymphoblastic leukemia and B cell differentiation blocks in primary Ab deficiencies.
  • [MeSH-minor] Adolescent. Cell Separation. Child. Child, Preschool. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2006 Jun 15;176(12):7787
  • (PMID = 16237084.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


21. Ran YC, Ao XX, Liu L, Fu YL, Tuo H, Xu F: [Distribution and drug resistance of pathogenic bacteria isolated from infected wounds of children after Wenchuan earthquake]. Zhonghua Er Ke Za Zhi; 2009 May;47(5):332-6; discussion 336-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acinetobacter baumanii was the most common organism isolated from wounds.
  • Drug sensitivity tests displayed that the isolated bacteria were highly resistant to common antibiotics.
  • One strain of Acinetobacter baumanii-calcoaceticus complex and six strains of Acinetobacter baumanii were resistant to all common antibiotics including imipenem/cilastatin.
  • CONCLUSION: Following the Wenchuan earthquake disaster, wound infection profiles of pediatric patients were significantly different, Acinetobacter baumanii was the main common organism isolated from wounds in contrast to the previous low isolation rate.


22. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J; 2010 Apr;159(4):532-538.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
  • BACKGROUND: Serial measurements of N-terminal pro-B type natriuretic peptide (NT-proBNP) provide prognostic information in patients with chronic heart failure (HF).
  • CONCLUSIONS: The Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study will test the hypothesis that therapy guided by NT-proBNP concentrations will be superior to standard of care HF management (www.clinicaltrials.gov identifier NCT00351390).

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20362709.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00351390
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


23. Liu YQ, Zhang YZ, Sun CY, Gao PJ: A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method. Am J Chin Med; 2005;33(4):671-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.
  • The antibacterial pharmacodynamics against E. coli of Chinese medicine (CM) Rhizoma coptidis (Coptis Root) and its formula Sanhuang, and the control antibiotics enoxacin, were analyzed by a concentration-killing curve (CKC) approach, and the novel parameters BC50 and r for antibacterial potency were proposed.
  • Using the agar plate method, about 400 cells of E. coli were evenly inoculated into LB agar plates containing a series of different concentrations of CM or antibiotic, and after a 24 hour incubation at 37 degrees C, all the viable colonies were enumerated.
  • This resulted in a sigmoid concentration-killing curve , in which No, that could be closely fitted (R2 > 0.9) with the function: N = 1 + e(r(x-BC50))/N0 in which N0, BC50 and r represent meaningfully inoculums size, median bactericidal concentration, and bactericidal intensity, respectively.
  • N modeled the survival of colony-forming units on each plate (CFU/plate) in a concentration series x of the drug.
  • The CKC was symmetrical about its single inflexion (BC50, N0/2).
  • Therefore theoretically, 2BC50 can replace MBC (minimum bactericidal concentration).
  • BC1 = BC50 + r/ln(N0-1), the drug concentration at r which only one colony survived, was the least critical value of MBC in CKC.
  • The parameters 2BC50 and BC1 agreed more closely with the definition of MBC, and were little affected by either the biochemical basis of the antibacterial or the inoculum's size (200-400 CFU/plate), and were determined by a multi-point curve.
  • As a result, these were more accurate, reproducible and practical as metrics than was the endpoint of MBC.
  • The two-dimensional CKC, involving BC50 and r, captures the intrinsic dynamics of the antibacterial effect of CM/strain versus concentration, and it is consistent with the Logistic equation of the bacterial growth curve in the format.
  • This verified approach has considerable value as a tool for the accurate and proper administration of CM.
  • The CKC of CM, different from that of antibiotics, is likely to be the resultant force of each ingredient in certain CM, which provides a clue to solve the problem of antibiotic resistance.
  • [MeSH-major] Escherichia coli / drug effects. Medicine, Chinese Traditional. Microbial Sensitivity Tests / methods. Models, Biological
  • [MeSH-minor] Coptis. In Vitro Techniques. Plant Bark. Reproducibility of Results. Rheum

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173540.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


24. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH: Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther; 2010;12(4):R154
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis (RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic site.
  • The RRs were elevated in RA patients across all common sites of osteoporotic fracture: hip (1.62, 95% CI 1.43 to 1.84), wrist (1.15, 95% CI 1.00 to 1.32), pelvis (2.02, 95% CI 1.77 to 2.30), and humerus (1.51, 95% CI 1.27 to 1.84).

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3790-8 [17136752.001]
  • [Cites] Arthritis Rheum. 2006 Oct;54(10):3104-12 [17009229.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906 [17870034.001]
  • [Cites] J Rheumatol. 2007 Oct;34(10):1971-5 [17896806.001]
  • [Cites] Clin Rheumatol. 2008 May;27(5):565-72 [17909741.001]
  • [Cites] Mod Rheumatol. 2008;18(2):170-6 [18297237.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1952-8 [18285417.001]
  • [Cites] Am Heart J. 2008 Aug;156(2):336-41 [18657665.001]
  • [Cites] Rheumatol Int. 2008 Sep;28(11):1143-50 [18446340.001]
  • [Cites] J Rheumatol. 2008 Sep;35(9):1704-8 [18634160.001]
  • [Cites] Arthritis Res Ther. 2008;10(4):R95 [18717997.001]
  • [Cites] Ann Rheum Dis. 2009 Mar;68(3):373-6 [18408246.001]
  • [Cites] Arthritis Res Ther. 2008;10(6):R128 [18986531.001]
  • [Cites] J Clin Rheumatol. 2009 Jun;15(4):155-60 [19363452.001]
  • [Cites] Menopause. 2009 Sep-Oct;16(5):950-5 [19387415.001]
  • [Cites] Semin Arthritis Rheum. 2009 Oct;39(2):116-22 [18585759.001]
  • [Cites] BMC Public Health. 2009;9:344 [19761614.001]
  • [Cites] JAMA. 2009 Nov 25;302(20):2214-21 [19934422.001]
  • [Cites] Curr Osteoporos Rep. 2009 Dec;7(4):134-9 [19968917.001]
  • [Cites] Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13 [20464374.001]
  • [Cites] Arthritis Rheum. 2000 Mar;43(3):522-30 [10728744.001]
  • [Cites] J Rheumatol. 2000 Nov;27(11):2582-9 [11093437.001]
  • [Cites] Rheum Dis Clin North Am. 2001 May;27(2):283-303 [11396093.001]
  • [Cites] Am J Epidemiol. 2001 Nov 1;154(9):854-64 [11682368.001]
  • [Cites] Ann Rheum Dis. 2003 Apr;62(4):347-9 [12634235.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):917-26 [12687533.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1066-76 [15077288.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1267-71 [15252210.001]
  • [Cites] Arthritis Rheum. 1984 Dec;27(12):1353-61 [6508860.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Rheumatol. 1991 Jun;18(6):804-8 [1895260.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] J Clin Epidemiol. 1992 Jul;45(7):703-14 [1619449.001]
  • [Cites] J Rheumatol. 1993 Oct;20(10):1666-9 [8295176.001]
  • [Cites] Ann Rheum Dis. 1994 Jan;53(1):18-23 [8311549.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Sep 15;19(18):2117-21 [7825055.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):767-73 [7862179.001]
  • [Cites] J Bone Miner Res. 1995 Feb;10(2):257-63 [7754805.001]
  • [Cites] Lancet. 1996 Jul 20;348(9021):145-9 [8684153.001]
  • [Cites] Bone. 1998 Aug;23(2):75-81 [9701464.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220-1 [10421309.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):323-37 [15862718.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):581-9 [15616758.001]
  • [Cites] Arch Intern Med. 2005 Jun 13;165(11):1293-7 [15956010.001]
  • [Cites] J Crit Care. 2005 Mar;20(1):12-9 [16015512.001]
  • [Cites] Osteoporos Int. 2005 Oct;16(10):1263-71 [15702263.001]
  • [Cites] J Bone Miner Res. 2007 Jul;22(7):1088-95 [17419681.001]
  • (PMID = 20682035.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR056215; United States / NIAMS NIH HHS / AR / P60 AR047782; United States / NIDCR NIH HHS / DE / R21 DE018750; United States / NIAMS NIH HHS / AR / K24 AR055989; United States / NIAMS NIH HHS / AR / AR055989; United States / NIAMS NIH HHS / AR / T32 AR 055885
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945054
  •  go-up   go-down


25. Winkel TA, Schouten O, Hoeks SE, Flu WJ, Hampton D, Kirchhof P, van Kuijk JP, Lindemans J, Verhagen HJ, Bax JJ, Poldermans D: Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. Am Heart J; 2010 Jun;159(6):1108-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac risk factors, inflammatory status, and left ventricular function (LVF; N-terminal pro-B-type natriuretic peptide and echocardiography) were assessed.
  • CONCLUSION: New-onset perioperative arrhythmias are common after vascular surgery.

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20569727.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Dieplinger B, Haltmayer M, Poelz W, Mueller T: Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study. Clin Chim Acta; 2009 Oct;408(1-2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have previously demonstrated that adiponectin is associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with peripheral artery disease (PAD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646980.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Biomarkers
  •  go-up   go-down


27. Deshpande VS, Kehrer JP: Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol; 2006 Aug 1;214(3):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nordihydroguaiaretic acid (NDGA), a general lipoxygenase (LOX) enzyme inhibitor, induces apoptosis independently of its activity as a LOX inhibitor in murine pro-B lymphocytes (FL.12 cells) by a mechanism that is still not fully understood.
  • [MeSH-minor] Acetylcysteine / pharmacology. Animals. Caspase 3. Caspases / metabolism. Cell Line. Cytochromes c / metabolism. Dithiothreitol / pharmacology. Electrophoresis, Polyacrylamide Gel. Enzyme Inhibitors / pharmacology. Mice. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473382.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Lipoxygenase Inhibitors; 7BO8G1BYQU / Masoprocol; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; T8ID5YZU6Y / Dithiothreitol; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


28. Truong QA, Siegel E, Karakas M, Januzzi JL Jr, Bamberg F, Mahabadi AA, Dasdemir S, Brady TJ, Bergmann A, Kunde J, Nagurney JT, Hoffmann U, Koenig W: Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial. Clin Chem; 2010 Apr;56(4):651-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined associations between amino-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM) concentrations and cardiac chamber volumes in chest pain patients without heart failure by use of computed tomography (CT).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2000 Apr;21(2):138-67 [10782362.001]
  • [Cites] J Intern Med. 2010 Jan;267(1):119-29 [19570053.001]
  • [Cites] Circulation. 2003 May 6;107(17):2207-12 [12695291.001]
  • [Cites] Heart. 2003 Jul;89(7):745-51 [12807847.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):234-6 [14709661.001]
  • [Cites] J Am Coll Cardiol. 2004 Jan 7;43(1):55-60 [14715184.001]
  • [Cites] Peptides. 2004 Aug;25(8):1369-72 [15350706.001]
  • [Cites] Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 [2520314.001]
  • [Cites] Endocrinology. 1993 May;132(5):1961-70 [8477647.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1105-9 [8097801.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60 [8387282.001]
  • [Cites] FEBS Lett. 1994 Jan 24;338(1):6-10 [8307158.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 30;201(3):1160-6 [8024557.001]
  • [Cites] Circulation. 1994 Jul;90(1):195-203 [8025996.001]
  • [Cites] J Clin Invest. 1996 May 15;97(10):2370-6 [8636418.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1823-9 [16099941.001]
  • [Cites] Clin Chem. 2006 May;52(5):827-31 [16543387.001]
  • [Cites] J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24 [16979009.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] J Card Fail. 2007 Feb;13(1):42-9 [17339002.001]
  • [Cites] J Am Coll Cardiol. 2007 Apr 10;49(14):1525-32 [17418290.001]
  • [Cites] J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80 [17996563.001]
  • [Cites] Clin Biochem. 2008 Mar;41(4-5):222-6 [18035345.001]
  • [Cites] Clin Chem Lab Med. 2008;46(2):204-11 [18076360.001]
  • [Cites] Clin Chim Acta. 2008 Jun;392(1-2):41-5 [18387360.001]
  • [Cites] J Am Coll Cardiol. 2008 May 13;51(19):1857-64 [18466800.001]
  • [Cites] Eur Radiol. 2008 Aug;18(8):1625-34 [18446346.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):305-11 [18628102.001]
  • [Cites] Int J Cardiol. 2008 Aug 18;128(2):244-9 [17673312.001]
  • [Cites] Circ J. 2008 Nov;72(11):1777-86 [18832779.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):80-7 [19332340.001]
  • [Cites] J Am Coll Cardiol. 2009 May 5;53(18):1642-50 [19406338.001]
  • [Cites] J Am Coll Cardiol. 2009 May 12;53(19):1783-90 [19422985.001]
  • [Cites] Regul Pept. 2009 Jun 5;155(1-3):33-8 [19328828.001]
  • [Cites] JAMA. 2009 Jul 1;302(1):49-57 [19567439.001]
  • [Cites] J Am Coll Cardiol. 2009 Jul 21;54(4):357-64 [19608034.001]
  • [Cites] Heart Fail Clin. 2009 Oct;5(4):489-500 [19631174.001]
  • [Cites] Heart. 2003 Feb;89(2):150-4 [12527664.001]
  • (PMID = 20185624.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32HL076136; United States / NHLBI NIH HHS / HL / L30 HL093806-01; United States / NHLBI NIH HHS / HL / T32 HL076136; United States / NHLBI NIH HHS / HL / L30HL093896; United States / NHLBI NIH HHS / HL / R01 HL080053; United States / NHLBI NIH HHS / HL / L30 HL093806; United States / NHLBI NIH HHS / HL / K23 HL098370; United States / NHLBI NIH HHS / HL / HL093806-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / proadrenomedullin; 114471-18-0 / Natriuretic Peptide, Brain; 148498-78-6 / Adrenomedullin
  • [Other-IDs] NLM/ NIHMS251716; NLM/ PMC2997388
  •  go-up   go-down


29. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer; 2005 May 23;92(10):1881-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
  • It has proved beneficial in treating patients with chronic myeloid leukaemia (CML).
  • The activity of IM in the blastic crisis of CML and against various myeloma cell lines suggests that this drug may also target other cellular components.
  • In the light of the important role of telomerase in malignant transformation, we evaluated the effect of IM on telomerase activity (TA) and regulation in various malignant cell lines.
  • Imatinib mesylate caused a dose-dependent inhibition of TA (up to 90% at a concentration of 15 microM IM) in c-kit-expressing SK-N-MC (Ewing sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer) and HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells), which do not express c-kit, BCR-ABL or PDGF-R.
  • The inhibition of proliferation was associated with a decrease in the S-phase of the cell cycle and an accumulation of cells in the G2/M phase.
  • This study demonstrates an additional cellular target of IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation.
  • [MeSH-minor] Animals. Benzamides. Cell Proliferation. Dose-Response Relationship, Drug. Down-Regulation. Fanconi Anemia / pathology. Humans. Imatinib Mesylate. Mice. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / pharmacology. Tumor Cells, Cultured


30. Godschalk PC, Gilbert M, Jacobs BC, Kramers T, Tio-Gillen AP, Ang CW, Van den Braak N, Li J, Verbrugh HA, Van Belkum A, Endtz HP: Co-infection with two different Campylobacter jejuni strains in a patient with the Guillain-Barré syndrome. Microbes Infect; 2006 Jan;8(1):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consequently, not all C. jejuni strains isolated from the faeces of a GBS patient are involved in the pathogenesis of GBS per se.
  • Furthermore, this is the first report in which cross-reactivity of antibodies to asialo-GM2 and to the LOS of a C. jejuni strain from a GBS patient has been demonstrated.


31. Gaukrodger N, Mayosi BM, Imrie H, Avery P, Baker M, Connell JM, Watkins H, Farrall M, Keavney B: A rare variant of the leptin gene has large effects on blood pressure and carotid intima-medial thickness: a study of 1428 individuals in 248 families. J Med Genet; 2005 Jun;42(6):474-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common polymorphisms of LEP have been associated with obesity, but their association with cardiovascular disease has been little studied.
  • We have examined the impact of both common and rare polymorphisms of the LEP gene on blood pressure (BP), subclinical atherosclerosis as measured by carotid intima-medial thickness (CIMT), and body mass index (BMI) in a large family study.
  • RESULTS: The polymorphisms typed captured all common haplotypes present at LEP.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]
  • [Cites] Obes Res. 1997 Jan;5(1):30-5 [9061713.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):259-66 [9634505.001]
  • [Cites] Hum Mol Genet. 1998 Oct;7(11):1745-51 [9736776.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3239-42 [9745435.001]
  • [Cites] Hypertension. 1999 May;33(5):1111-7 [10334796.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):279-92 [10631157.001]
  • [Cites] Ann Hum Genet. 1999 May;63(Pt 3):227-34 [10738535.001]
  • [Cites] J Hum Hypertens. 2000 Sep;14(9):573-9 [10980589.001]
  • [Cites] Diabetes. 2000 Dec;49(12):2196-200 [11118025.001]
  • [Cites] Am J Hypertens. 2001 Feb;14(2):91-7 [11243313.001]
  • [Cites] Ann Hum Genet. 2000 Sep;64(Pt 5):391-4 [11281277.001]
  • [Cites] Hypertension. 2001 May;37(5):1236-41 [11358934.001]
  • [Cites] J Hypertens. 2001 May;19(5):871-7 [11393669.001]
  • [Cites] Mol Cell Biochem. 2001 Aug;224(1-2):53-67 [11693200.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1706-9 [11926895.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2909-12 [12050272.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):544-8 [12110843.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1963-71 [12473259.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1903-13 [12493255.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):112-7 [14615386.001]
  • [Cites] Circulation. 2004 Mar 9;109(9):1089-94 [14993130.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):421-3 [15026459.001]
  • [Cites] Science. 2004 Aug 6;305(5685):869-72 [15297675.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):220-30 [15197684.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2691-7 [15345705.001]
  • [Cites] Hypertension. 1989 Jun;13(6 Pt 2):884-9 [2737726.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1158-9 [8097848.001]
  • [Cites] Circulation. 1993 Jul;88(1):20-8 [8319334.001]
  • [Cites] Genet Epidemiol. 1993;10(3):145-58 [8349098.001]
  • [Cites] Diabetes Care. 1999 Nov;22(11):1851-7 [10546019.001]
  • [Cites] Circulation. 1995 Oct 15;92(8):2127-34 [7554192.001]
  • [Cites] Diabetes. 1996 May;45(5):679-82 [8621022.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • (PMID = 15937081.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400874; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ PMC1736073
  •  go-up   go-down


32. Melchers F: Starting at the end. Eur J Immunol; 2007 Nov;37 Suppl 1:S125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After more than 40 years in immunology, I have moved "backwards" over mature B cells, immature B cells, precursor B cells and lymphocyte progenitors to pluripotent hematopoietic stem cells.
  • Initially it was an intellectual exercise to trace the unknown progenitor of known B-lineage cells; now it has become an experimental approach - to de- and re-differentiate B-lineage cells to earlier differentiation stages and to other lineages of hematopoietic cells.
  • [MeSH-major] Allergy and Immunology / history. B-Lymphocytes / cytology. Cell Differentiation / immunology. Hematopoietic Stem Cells / cytology. Precursor Cells, B-Lymphoid / cytology
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Lineage / immunology. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972356.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies
  • [Personal-name-as-subject] Melchers F
  •  go-up   go-down


33. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K: Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol; 2010 Oct;38(10):885-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
  • OBJECTIVE: Cytotoxic ligands are involved in tumor immunity and graft-vs.-leukemia effect after allogeneic stem cell transplantation for leukemia.
  • To clarify the susceptibility of T-cell acute lymphoblastic leukemia (T-ALL) to tumor immunity, sensitivity to recombinant human soluble Fas ligand (rhsFasL) and tumor necrosis factor-related apoptosis-inducing ligand (rhsTRAIL) was determined.
  • MATERIALS AND METHODS: Sensitivity to rhsFasL and rhsTRAIL and cell surface expression of their receptors were tested in T-ALL cell lines (n = 7) and patients' samples (n = 17) and compared with those in B-precursor ALL cell lines (n = 30).
  • Expression of components of the death-inducing signaling complex and the TRAIL receptor genes (DR4/DR5), and the methylation status and promoter activity of the DR4/DR5 gene were tested in T-ALL cell lines.
  • RESULTS: T-ALL cell lines showed higher level of Fas expression and higher sensitivity to rhsFasL than did B-precursor ALL cell lines.
  • Despite comparable expression of components of death-inducing signaling complex, cell lines and patients' samples of T-ALL showed TRAIL-resistance associated with low cell surface expression of DR4/DR5.
  • Gene expression of DR4/DR5 in T-ALL cell lines was significantly lower than that in B-precursor ALL cell lines, and the methylation status of the gene promoter in T-ALL cell lines was associated with the gene expression level at least for DR4.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Fas Ligand Protein / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Antigens, CD95 / metabolism. Cell Line, Tumor. Cells, Cultured. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Drug Resistance. Flow Cytometry. Gene Expression / drug effects. Humans. Immunoblotting. Jurkat Cells. Luciferases / genetics. Luciferases / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20670671.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Fas Ligand Protein; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.13.12.- / Luciferases
  •  go-up   go-down


34. Forester CM, Braunreiter CL, Yaish H, Hedlund GL, Afify Z: Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia. Pediatr Radiol; 2009 Nov;39(11):1230-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.
  • In children, leukemia is the most common malignancy, and approximately 75% of leukemias are acute lymphoblastic leukemia (ALL).
  • Central nervous system leukemia is found at diagnosis in fewer than 5% of children with ALL.
  • Leukemic intracranial masses have been described with acute myeloid leukemia, but ALL presenting as a mass lesion is rare.
  • We describe a unique case of an intracranial confirmed precursor B cell (pre-B) ALL mass in a 13-year-old girl that was diagnosed by brain CT, MRI and cerebral angiography, and confirmed by biopsy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Angiography / methods. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tomography, X-Ray Computed / methods


35. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES, Schindler J: A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Dec;31(12):936-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children.
  • Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with pre-B ALL.
  • CONCLUSIONS: Combotox can be safely administered to children with refractory leukemia.
  • [MeSH-major] Immunotoxins / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ricin / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875969.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / CD22 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 9009-86-3 / Ricin
  •  go-up   go-down


36. Forestier E, Gauffin F, Andersen MK, Autio K, Borgström G, Golovleva I, Gustafsson B, Heim S, Heinonen K, Heyman M, Hovland R, Johannsson JH, Kerndrup G, Rosenquist R, Schoumans J, Swolin B, Johansson B, Nordgren A, Nordic Society of Pediatric Hematology and Oncology, Swedish Cytogenetic Leukemia Study Group, NOPHO Leukemia Cytogenetic Study Group: Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer; 2008 Feb;47(2):149-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature.
  • Although dic(9;20)(p13.2;q11.2) is a characteristic abnormality in childhood B-cell precursor acute lymphoblastic leukemias (BCP ALL), little is known about its clinical impact or the type and frequency of additional aberrations it may occur together with.
  • Consistent immunophenotypic features of the Nordic cases included positivity for HLA-DR, CD10, CD19, CD20, and CD22 and negativity for T-cell and myeloid markers; no detailed immunophenotypes were reported for the previously published cases.
  • The median patient age was 3 years, the female/male ratio was 2.0, the median white blood cell count was 24 x 10(9)/l, 11% had central nervous system involvement, and 5% had a mediastinal mass at diagnosis.
  • Thus, although relapses are quite common, postrelapse treatment of many patients is successful.
  • [MeSH-major] Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Cytogenetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17990329.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


37. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS: Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother; 2009 Sep;53(9):3690-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-beta-D-glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme.
  • However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of > or = 2 microg/ml for the three echinocandin drugs.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Mycol. 2001;39 Suppl 1:55-66 [11800269.001]
  • [Cites] J Clin Microbiol. 2007 Jan;45(1):70-5 [17079501.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Oct;46(10):3268-72 [12234857.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3551-7 [12354845.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Aug;12(8):1313-33 [12882619.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5729-31 [14662968.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3137-41 [15243072.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Aug;48(8):3107-11 [15273127.001]
  • [Cites] Clin Infect Dis. 2004 Aug 1;39(3):309-17 [15306996.001]
  • [Cites] Rev Iberoam Micol. 2003 Dec;20(4):121-36 [15456349.001]
  • [Cites] Antimicrob Agents Chemother. 1991 Jan;35(1):99-103 [1826595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12907-11 [7528927.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):80-96 [9880475.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73 [16048935.001]
  • [Cites] J Clin Microbiol. 2005 Aug;43(8):4107-11 [16081957.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Antimicrob Agents Chemother. 2007 May;51(5):1616-20 [17307976.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6 [17420211.001]
  • [Cites] Drug Resist Updat. 2007 Jun;10(3):121-30 [17569573.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6 [17785512.001]
  • [Cites] J Clin Microbiol. 2008 Feb;46(2):551-9 [18094129.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5 [18378714.001]
  • [Cites] Cancer. 2008 Jun;112(11):2493-9 [18412153.001]
  • [Cites] EMBO J. 2008 Jun 4;27(11):1585-95 [18451801.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12 [18443110.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2620-9 [18579718.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5 [18676885.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Nov;52(11):4181-3 [18794386.001]
  • [Cites] Genetics. 2008 Nov;180(3):1391-405 [18791219.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jan;53(1):112-22 [18955538.001]
  • [Cites] Int J Syst Evol Microbiol. 2006 Jan;56(Pt 1):313-7 [16403904.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Aug;50(8):2892-4 [16870797.001]
  • [Cites] J Clin Microbiol. 2006 Oct;44(10):3533-8 [17021079.001]
  • [Cites] Clin Infect Dis. 2002 Sep 1;35(5):627-30 [12173140.001]
  • (PMID = 19546367.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI069397; United States / NIAID NIH HHS / AI / AI069397
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Fungal Proteins; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.34 / 1,3-beta-glucan synthase
  • [Other-IDs] NLM/ PMC2737881
  •  go-up   go-down


38. Moberg C, Alderling M, Meding B: Hand eczema and quality of life: a population-based study. Br J Dermatol; 2009 Aug;161(2):397-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hand eczema is a common disease in the population and is of interest from a public health perspective.
  • The EQ-5D index for hand eczema was of the same size as for psoriasis and asthma, all common diseases with an impact on public health.

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302069.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Toungoussova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P: Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis; 2005 Mar;24(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidrug-resistant tuberculosis has become common all over the world, necessitating the inclusion of second-line drugs in treatment regimens.

  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. CAPREOMYCIN .
  • Hazardous Substances Data Bank. ETHIONAMIDE .
  • Hazardous Substances Data Bank. KANAMYCIN A .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2002 Apr 15;185(8):1197-202 [11930334.001]
  • [Cites] BMJ. 2003 Mar 15;326(7389):574 [12637401.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):1930-7 [12037045.001]
  • [Cites] Int J Tuberc Lung Dis. 2002 May;6(5):406-14 [12019916.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3179-86 [10488174.001]
  • [Cites] Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5 [11326818.001]
  • [Cites] Clin Infect Dis. 2003 Sep 1;37(5):665-72 [12942398.001]
  • [Cites] Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207 [11144553.001]
  • [Cites] Lancet. 2002 Jun 8;359(9322):1980-9 [12076553.001]
  • [Cites] Clin Microbiol Rev. 1995 Oct;8(4):496-514 [8665467.001]
  • (PMID = 15742171.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents; 11003-38-6 / Capreomycin; 59-01-8 / Kanamycin; A4P49JAZ9H / Ofloxacin; OAY8ORS3CQ / Ethionamide
  •  go-up   go-down


40. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol; 2009 Jan;144(2):147-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.
  • Cytogenetics has determined the incidence and prognostic significance of chromosomal abnormalities in acute lymphoblastic leukaemia (ALL).
  • Five 'hot topics' are presented in which cytogenetics and related techniques have been instrumental in understanding the role of genetics in leukaemogenesis: (i) genetic changes are integral to the biology of T-cell ALL;.
  • (ii) intrachromosomal amplification of chromosome 21 is a new recurrent abnormality in precursor-B ALL (BCP-ALL);.
  • (iv) alterations in genes involved in B-cell development and cell cycle control contribute to the pathogenesis of BCP-ALL;.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006567.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  •  go-up   go-down


41. Russell T, Oliver JM, Wilson BS, Tarleton CA, Winter SS, Meng X: Differential expression of Ikaros isoforms in monozygotic twins with MLL-rearranged precursor-B acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Dec;30(12):941-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of Ikaros isoforms in monozygotic twins with MLL-rearranged precursor-B acute lymphoblastic leukemia.
  • Infant leukemia associated with rearrangement of the MLL gene typically presents with high-risk clinical features.
  • Relapse is common despite aggressive therapy and perturbations in signaling pathways may contribute to disease resistance.
  • We evaluated twin 4-month-old monozygotic baby boys who presented with MLL-rearranged precursor-B acute lymphoblastic leukemia.
  • However, the dominant-negative Ik8 isoform was detected in only 1 boy, suggesting a common genetic ontogeny that was modulated by leukemic evolution.
  • [MeSH-major] Diseases in Twins / genetics. Gene Rearrangement. Ikaros Transcription Factor / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Twins, Monozygotic
  • [MeSH-minor] Acid Anhydride Hydrolases / genetics. Acute Disease. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 4 / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Infant. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Protein Isoforms / genetics. Translocation, Genetic. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131787.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IKZF1 protein, human; 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Protein Isoforms; 0 / fragile histidine triad protein; 148971-36-2 / Ikaros Transcription Factor; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


42. Ma J, Sun H, Chen SM, Liu LX, Chen SQ, Liu YF, Xie XS, Meng XL, Deng M, Zhang QT, Li T: [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia].
  • The aim of this study was to explore the clinical features and survival of adult patients with CD20 positive B-lineage acute lymphoblastic leukemia (B-ALL).
  • The results showed that among 119 cases, CD20 positive B-ALL accounted for 40 cases (33.61%), CD20 negative B-ALL patents accounted for 79 cases (66.39), the percentage of male patients in CD20 positive and negative groups were 72.50% and 50.63%, the leukocyte counts at diagnosis in these two groups were (27.35+/-30.29)x10(9)/L and (0.11+/-81.72)x10(9)/L, respectively, there were significant differences (p<0.05), whereas the distribution of age, infiltration of liver, spleen, lymph nodes and central nervous system, the hemoglobin and platelet levels, the expression of myeloid lineage marker, the incidence of Ph chromosome, the ratio of hyperdiploid and normal karyotype, the complete remission rate within 4 weeks, induction death rate and relapse rate and so on in CD20 positive and negative groups showed no significant differences (p>0.05).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416193.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


43. Sabbattini P, Dillon N: The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development. Semin Immunol; 2005 Apr;17(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development.
  • The lambda5 and VpreB genes encode the components of the surrogate light-chain, which forms part of the pre-B cell receptor.
  • Activation of the genes in pro-B cells depends on the combined effects of early B cell factor (EBF) and the E2A factors E12 and E47.
  • Silencing of lambda5 expression in mature B cells occurs through the action of Ikaros on the gene promoter where it may compete for binding of EBF and initiate the formation of a silent chromatin structure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737573.001).
  • [ISSN] 1044-5323
  • [Journal-full-title] Seminars in immunology
  • [ISO-abbreviation] Semin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Membrane Glycoproteins; 0 / Transcription Factors
  • [Number-of-references] 56
  •  go-up   go-down


44. Goei D, Flu WJ, Hoeks SE, Galal W, Dunkelgrun M, Boersma E, Kuijper R, van Kuijk JP, Winkel TA, Schouten O, Bax JJ, Poldermans D: The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients. Anesth Analg; 2009 Nov;109(5):1403-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
  • INTRODUCTION: N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts adverse cardiac outcome in patients undergoing vascular surgery.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843778.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hemoglobins; 0 / Peptide Fragments; 0 / Troponin T; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


45. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG: The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J; 2006 Oct;27(19):2353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
  • AIMS: To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of major structural heart disease (MSHD) in patients with atrial fibrillation (AF) compared with those with sinus rhythm (SR) using receiver operator characteristic (ROC) analysis.
  • AF, a common finding in HF and MSHD, is also associated with raised plasma NT-proBNP.
  • [MeSH-major] Atrial Fibrillation / blood. Heart Failure / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood
  • [MeSH-minor] Aged. Echocardiography. Female. Humans. Male. Predictive Value of Tests. Regression Analysis. Ventricular Dysfunction, Left / diagnosis


46. MacKinnon N, Ridgway J, Crowell KJ, Macdonald PM: Aluminum binding to phosphatidylcholine lipid bilayer membranes: aluminum exchange lifetimes from 31P NMR spectroscopy. Chem Phys Lipids; 2006 Feb;139(2):85-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the temperature range from 5 to 35 degrees C all three exchange rate constants increased by roughly an order of magnitude from k approximately 1-2 to 10-14s(-1), exhibiting Arrhenius behavior with activation energies on the order of 30-45 kJ mol(-1) and correspondingly positive enthalpies of activation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336955.001).
  • [ISSN] 0009-3084
  • [Journal-full-title] Chemistry and physics of lipids
  • [ISO-abbreviation] Chem. Phys. Lipids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Lipid Bilayers; 0 / Membranes, Artificial; 0 / Phosphatidylcholines; 0 / Phosphorus Isotopes; CPD4NFA903 / Aluminum
  •  go-up   go-down


47. Schelonka RL, Ivanov II, Vale AM, Szymanska E, Zemlin M, Gartland GL, Schroeder HW Jr: The CDR-H3 repertoire from TdT-deficient adult bone marrow is a close, but not exact, homologue of the CDR-H3 repertoire from perinatal liver. J Immunol; 2010 Nov 15;185(10):6075-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V(H)7183-containing VDJCμ transcripts from these cells were amplified, cloned, sequenced, and compared with transcripts from wild-type perinatal liver and adult BM.
  • What minor differences were detected in the pro-B cell stage tended to diminish with B cell maturation, suggesting strong environmental or Ag-driven pressure to achieve a specific range of V(H)DJ(H) usage regardless of the extent of N nucleotide addition.
  • However, although the patterns of V(H)DJ(H) usage in the TdT-deficient B lineage cells paralleled that of wild-type adult cells, the length distribution, global amino acid composition, and charge distribution of the CDR-H3 repertoire proved to be a close, although not exact, homologue of the CDR-H3 repertoire first expressed by late pre-B cells in the TdT-insufficient perinatal liver.
  • Thus, although differing in V(H) content, TdT-deficient mice appear to represent a good, although not perfect, model for testing the role of perinatal CDR-H3 limitations on late B cell development and Ab responses.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2000 Jan;94(1):24-32 [10607487.001]
  • [Cites] Immunogenetics. 2010 Oct;62(10):653-66 [20714894.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):257-63 [11418657.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3486-93 [11544342.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):440-4 [12540919.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):444-8 [12540920.001]
  • [Cites] Clin Immunol. 2003 Jun;107(3):186-97 [12804532.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4624-9 [15034081.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):4118-22 [6287467.001]
  • [Cites] Nature. 1983 Apr 14;302(5909):575-81 [6300689.001]
  • [Cites] Annu Rev Biochem. 1984;53:595-623 [6383201.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):727-33 [6092962.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):752-5 [6092963.001]
  • [Cites] J Exp Med. 1990 Jan 1;171(1):265-92 [2104919.001]
  • [Cites] EMBO J. 1990 Jul;9(7):2133-40 [2113468.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4343-50 [1753104.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):222-9 [1607655.001]
  • [Cites] EMBO J. 1993 May;12(5):1819-26 [8491175.001]
  • [Cites] Science. 1993 Aug 27;261(5125):1171-5 [8356451.001]
  • [Cites] Mol Immunol. 1994 Feb;31(3):169-217 [8114766.001]
  • [Cites] J Immunol. 1996 Mar 15;156(6):2077-84 [8690895.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):600-3 [8698848.001]
  • [Cites] Immunol Rev. 1995 Dec;148:201-19 [8825288.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):1-8 [8980108.001]
  • [Cites] J Mol Biol. 1998 Jul 3;280(1):1-9 [9653027.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):7023-30 [9862739.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):188-97 [10428499.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7773-80 [15944280.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6624-32 [16272317.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):293-301 [16429139.001]
  • [Cites] J Exp Med. 2006 Jun 12;203(6):1567-78 [16754718.001]
  • [Cites] Eur J Immunol. 2007 Apr;37(4):1010-21 [17345580.001]
  • [Cites] J Virol. 2007 Sep;81(17):9331-8 [17567700.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8416-24 [19050259.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):851-8 [20018621.001]
  • [Cites] Immunity. 2000 Jul;13(1):37-45 [10933393.001]
  • (PMID = 20956348.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ HM154548/ HM154549/ HM154550/ HM154551/ HM154552/ HM154553/ HM154554/ HM154555/ HM154556/ HM154557/ HM154558/ HM154559/ HM154560/ HM154561/ HM154562/ HM154563/ HM154564/ HM154565/ HM154566/ HM154567/ HM154568/ HM154569/ HM154570/ HM154571/ HM154572/ HM154573/ HM154574/ HM154575/ HM154576/ HM154577/ HM154578/ HM154579/ HM154580/ HM154581/ HM154582/ HM154583/ HM154584/ HM154585/ HM154586/ HM154587/ HM154588/ HM154589/ HM154590/ HM154591/ HM154592/ HM154593/ HM154594/ HM154595/ HM154596/ HM154597/ HM154598/ HM154599/ HM154600/ HM154601/ HM154602/ HM154603/ HM154604/ HM154605/ HM154606/ HM154607/ HM154608/ HM154609/ HM154610/ HM154611/ HM154612/ HM154613/ HM154614/ HM154615/ HM154616/ HM154617/ HM154618/ HM154619/ HM154620/ HM154621/ HM154622/ HM154623/ HM154624/ HM154625/ HM154626/ HM154627/ HM154628/ HM154629/ HM154630/ HM154631/ HM154632/ HM154633/ HM154634/ HM154635/ HM154636/ HM154637/ HM154638/ HM154639/ HM154640/ HM154641/ HM154642/ HM154643/ HM154644/ HM154645/ HM154646/ HM154647/ HM154648/ HM154649/ HM154650/ HM154651/ HM154652/ HM154653/ HM154654/ HM154655/ HM154656/ HM154657/ HM154658/ HM154659/ HM154660/ HM154661/ HM154662/ HM154663/ HM154664/ HM154665/ HM154666/ HM154667/ HM154668/ HM154669/ HM154670/ HM154671/ HM154672/ HM154673/ HM154674/ HM154675/ HM154676/ HM154677/ HM154678/ HM154679/ HM154680/ HM154681/ HM154682/ HM154683/ HM154684/ HM154685/ HM154686/ HM154687/ HM154688/ HM154689/ HM154690/ HM154691/ HM154692/ HM154693/ HM154694/ HM154695/ HM154696/ HM154697/ HM154698/ HM154699/ HM154700/ HM154701/ HM154702/ HM154703/ HM154704/ HM154705/ HM154706/ HM154707/ HM154708/ HM154709/ HM154710/ HM154711/ HM154712/ HM154713/ HM154714/ HM154715/ HM154716/ HM154717/ HM154718/ HM154719/ HM154720/ HM154721/ HM154722/ HM154723/ HM154724/ HM154725/ HM154726/ HM154727/ HM154728/ HM154729/ HM154730/ HM154731/ HM154732/ HM154733/ HM154734/ HM154735/ HM154736/ HM154737/ HM154738/ HM154739/ HM154740/ HM154741/ HM154742/ HM154743/ HM154744/ HM154745/ HM154746/ HM154747/ HM154748/ HM154749/ HM154750/ HM154751/ HM154752/ HM154753/ HM154754/ HM154755/ HM154756/ HM154757/ HM154758/ HM154759/ HM154760/ HM154761/ HM154762/ HM154763/ HM154764/ HM154765/ HM154766/ HM154767/ HM154768/ HM154769/ HM154770/ HM154771/ HM154772/ HM154773/ HM154774/ HM154775/ HM154776/ HM154777/ HM154778/ HM154779/ HM154780/ HM154781/ HM154782/ HM154783/ HM154784/ HM154785/ HM154786/ HM154787/ HM154788/ HM154789/ HM154790/ HM154791/ HM154792/ HM154793/ HM154794/ HM154795/ HM154796/ HM154797/ HM154798/ HM154799/ HM154800/ HM154801/ HM154802/ HM154803/ HM154804/ HM154805/ HM154806/ HM154807/ HM154808/ HM154809/ HM154810/ HM154811/ HM154812/ HM154813/ HM154814/ HM154815/ HM154816/ HM154817/ HM154818/ HM154819/ HM154820/ HM154821/ HM154822/ HM154823/ HM154824/ HM154825/ HM154826/ HM154827/ HM154828/ HM154829/ HM154830/ HM154831/ HM154832/ HM154833/ HM154834/ HM154835/ HM154836/ HM154837/ HM154838/ HM154839/ HM154840/ HM154841/ HM154842/ HM154843/ HM154844/ HM154845/ HM154846/ HM154847/ HM154848/ HM154849/ HM154850/ HM154851/ HM154852/ HM154853/ HM154854/ HM154855/ HM154856/ HM154857/ HM154858/ HM154859/ HM154860/ HM154861/ HM154862/ HM154863/ HM154864/ HM154865/ HM154866/ HM154867/ HM154868/ HM154869/ HM154870/ HM154871/ HM154872/ HM154873/ HM154874/ HM154875/ HM154876/ HM154877/ HM154878/ HM154879/ HM154880/ HM154881/ HM154882/ HM154883/ HM154884/ HM154885/ HM154886/ HM154887/ HM154888/ HM154889/ HM154890/ HM154891/ HM154892/ HM154893/ HM154894/ HM154895/ HM154896/ HM154897/ HM154898/ HM154899/ HM154900/ HM154901/ HM154902/ HM154903/ HM154904/ HM154905/ HM154906/ HM154907/ HM154908/ HM154909/ HM154910/ HM154911/ HM154912/ HM154913/ HM154914/ HM154915/ HM154916/ HM154917/ HM154918/ HM154919/ HM154920/ HM154921/ HM154922/ HM154923/ HM154924/ HM154925/ HM154926/ HM154927/ HM154928/ HM154929/ HM154930/ HM154931/ HM154932/ HM154933/ HM154934/ HM154935/ HM154936
  • [Grant] United States / NIAID NIH HHS / AI / AI007051; United States / NIAID NIH HHS / AI / T32 AI007051; United States / NIAID NIH HHS / AI / AI048115; United States / NIAID NIH HHS / AI / AI078449; United States / NIAID NIH HHS / AI / R56 AI048115; United States / NIAID NIH HHS / AI / R21 AI078449; United States / NIAID NIH HHS / AI / R01 AI048115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  • [Other-IDs] NLM/ NIHMS469908; NLM/ PMC3670101
  •  go-up   go-down


48. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL: Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail; 2006 Oct;12(8):635-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction.
  • BACKGROUND: Cardiotrophin-1 (CT-1) is an important inflammatory cytokine; its presence has been documented in patients after acute myocardial infarction (AMI).
  • We sought to investigate this and compared it with N terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of death or heart failure.

  • Genetic Alliance. consumer health - Myocardial infarction 1.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Card Fail. 2006 Oct;12(8):641-3 [17045184.001]
  • (PMID = 17045183.001).
  • [ISSN] 1532-8414
  • [Journal-full-title] Journal of cardiac failure
  • [ISO-abbreviation] J. Card. Fail.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Peptide Fragments; 0 / cardiotrophin 1; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


49. Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, Hakim G: NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res; 2009;43(11):1111-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells.
  • The mechanism involved in the prosurvival effect of interleukin-3 on the human acute myeloid leukaemia cell line M07e is investigated.
  • A decrease in intracellular reactive oxygen species (ROS) content, glucose transport activity and cell survival was observed in the presence of inhibitors of plasma membrane ROS sources, such as diphenylene iodonium and apocynin, and by small interference RNA for Nox2.
  • Thus, the inhibition of ROS generation by Nox inhibitors stimulated apoptosis showing that ROS production, induced by IL-3 via Nox2, protects leukaemic cells from cell death.
  • Also incubation with receptor tyrosine kinase inhibitors, such as anti-leukaemic drugs blocking the stem cell factor receptor (c-kit), showed similar effects, hinting that IL-3 transmodulates c-kit phosphorylation.
  • These mechanisms may play an important role in acute myeloid leukaemia treatment, representing a novel therapeutic target.
  • [MeSH-major] Leukemia, Myeloid, Acute / enzymology. Membrane Glycoproteins / metabolism. NADPH Oxidase / metabolism
  • [MeSH-minor] Biological Transport. Cell Line, Tumor. Cell Survival / physiology. Glucose Transporter Type 1 / metabolism. Humans. Interleukin-3 / metabolism. Phosphorylation / drug effects. Reactive Oxygen Species / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707918.001).
  • [ISSN] 1029-2470
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CYBB protein, human; 0 / Glucose Transporter Type 1; 0 / Interleukin-3; 0 / Membrane Glycoproteins; 0 / Reactive Oxygen Species; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


50. Mansson R, Zandi S, Welinder E, Tsapogas P, Sakaguchi N, Bryder D, Sigvardsson M: Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity. Blood; 2010 Apr 1;115(13):2601-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity.
  • This allowed us to subfractionate common lymphoid progenitors and pre-pro-B (fraction A) cells into lambda5(-)Rag1(low), lambda5(-)Rag1(high), and lambda5(+)Rag1(high) cells.
  • Rag1(high) cells displayed reduced NK-cell potential with preserved capacity to generate B- and T-lineage cells, whereas the lambda5(+) cells were B-lineage restricted.
  • These data suggest that the classic common lymphoid progenitor compartment composes a mixture of cells with relatively restricted lineage potentials, thus opening new possibilities to investigate early hematopoiesis.
  • [MeSH-minor] Animals. Antigens, Ly / biosynthesis. Antigens, Ly / genetics. B-Cell-Specific Activator Protein / biosynthesis. B-Cell-Specific Activator Protein / genetics. Biomarkers. Cell Lineage. Cells, Cultured / cytology. Cells, Cultured / metabolism. Coculture Techniques. Flow Cytometry. GPI-Linked Proteins. Gene Expression Profiling. Gene Knock-In Techniques. Genes, Reporter. Homeodomain Proteins / genetics. Killer Cells, Natural / cytology. Lymphocyte Subsets / cytology. Lymphopoiesis. Mice. Mice, Transgenic. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / biosynthesis. Trans-Activators / genetics


51. Manosroi A, Khositsuntiwong N, Götz F, Werner RG, Manosroi J: Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res; 2009;19(2):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles.
  • Transdermal absorption of luciferase plasmid (pLuc) was enhanced by loading in elastic cationic liposomes and niosomes and the application of iontophoresis or the stratum corneum (SC) stripping method.
  • Cationic liposomes (DPPC/Chol/DDAB at a 1:1:1 molar ratio) and niosomes (Tween61/Chol/DDAB at a 1:1:0.5 molar ratio) were prepared by the freeze-dried empty liposomes method.
  • The elastic vesicles were prepared by hydrating the lipid or surfactant film by 25% of ethanol instead of distilled water.
  • Gel electrophoresis of all nanovesicles showed the 100% pLuc entrapment efficiency.
  • All nanovesicles loaded with pLuc showed larger vesicular sizes than the nonloaded vesicles of about 1.4 times for liposomes and 1.7 times for niosomes.
  • The nanovesicles loaded with pLuc demonstrated less positive zeta potential than the nonloaded vesicles.
  • The pLuc loaded in elastic vesicles kept at 4 +/- 2 and 27 +/- 2 degrees C for 8 weeks gave the remaining pLuc of about 70 and 60% for liposomes and 85 and 73% for niosomes, respectively.
  • For nonelastic vesicles kept at 4 +/- 2 degrees C, 56 and 61% of the remaining pLuc were observed for liposomes and niosomes, respectively, while at 27 +/- 2 degrees C, all pLuc were degraded.
  • The deformability indices of the elastic liposomes and niosomes loaded with the pLuc were 16.64 +/- 2.92 and 20.72 +/- 0.82, whereas the nonelastic vesicles gave 9.35 +/- 0.09 and 10.08 +/- 0.12, respectively.
  • Transdermal absorption through rat skin pretreated with SC stripping or treated with iontophoresis of pLuc loaded in nanovesicles by vertical Franz diffusion cells was investigated at 37 degrees C.
  • The cells were stopped and the skin and the receiving solution were withdrawn at 1, 3, and 6 hours and the pLuc contents in the stripped SC, whole skin (viable epidermis and dermis; VED), and the receiving solution were assayed by the modified gel electrophoresis and gel documentation.
  • Without the SC stripping technique or iontophoresis, the pLuc loaded and nonloaded in nonelastic cationic liposomes or niosomes were not found in SC, VED, and receiving solution.
  • The fluxes in the whole skin of pLuc loaded in nonelastic liposomes and niosomes with SC stripping and iontophoresis at 6 hours gave 2.73 +/- 0.46 and 3.83 +/- 0.73, and 7.01 +/- 1.22 and 9.60 +/- 1.31 g/cm(2)/h, respectively, while pLuc loaded in elastic liposomes and niosomes without the SC stripping and iontophoresis at 6 hours showed 2.79 +/- 0.09 and 2.84 +/- 0.04 g/cm(2)/h, respectively.
  • The pLuc loaded in elastic niosomes or in nonelastic niosomes with iontophoresis was found in the receiving solution with a higher amount than that loaded in elastic liposomes or nonelastic liposomes with iontophoresis.
  • The fluxes in the receiving solution of pLuc loaded in nonelastic liposomes and niosomes with iontophoresis at 6 hours were 6.71 +/- 0.31 and 8.82 +/- 0.28 g/cm(2)/h, respectively.
  • For elastic liposomes and niosomes, the fluxes of the loaded pLuc in the receiving solution were the same, at about 1.9 g/cm(2)/h.
  • Although pLuc loaded in nonelastic niosomes with iontophoresis gave the highest delivery of the plasmid in VED and receiving solution, a more promising applicable approach for gene delivery has been suggested to be the elastic niosomal systems, since no equipment is required.
  • [MeSH-major] Plasmids / metabolism. Skin / metabolism
  • [MeSH-minor] Administration, Cutaneous. Animals. Cations / metabolism. DNA / metabolism. Freeze Drying. Liposomes / metabolism. Luciferases / metabolism. Male. Quaternary Ammonium Compounds. Rats. Rats, Sprague-Dawley. Surface-Active Agents / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241277.001).
  • [ISSN] 1532-2394
  • [Journal-full-title] Journal of liposome research
  • [ISO-abbreviation] J Liposome Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cations; 0 / Liposomes; 0 / Quaternary Ammonium Compounds; 0 / Surface-Active Agents; 13146-86-6 / didodecyldimethylammonium; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


52. Wu M, Sun XF, Xu ZM, Zhang XY, Li FR, Wang XG, Chen XL, Lin HQ, Wen HG, Sun X, Song TW: [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug;13(4):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
  • To test the European BIOMED-1 Concerted Action proposed technique to detect minimal residual disease (MRD) in the chinese patients with precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) by triple-staining flow cytometry and to define both normal and aberrant phenotypic profiles of precursor B cells, a series of bone marrow samples, 35 from precursor-B-ALL (13 in newly diagnosed cases, 15 at the end of remission induction therapy and 7 at end of the consolidations), and 19 from normal controls, were immunophenotyped with the five triple-staining antibodies (TdT/CD10/CD19, CD10/CD20/CD19, CD34/CD38/CD19, CD34/CD22/CD19 and CD19/CD34/CD45) recom-mended by the BIOMED-1 using common flow cytometric protocols.
  • The results showed that three major CD19(+) cell subpopulations were identified in the normal controls, representing three consecutive maturation stages.
  • The subpopulations in the precursor-B-ALL cases disappeared and were replaced with a great number of luekemic cells which had different characteristics of phenotypes, and then they reappeared with almost same characteristics as the normal CD19(+) cells after the patients achieved complete remission.
  • When the five triple-staining antibody combinations were used, the phenotypic aberrancies could be identified in 12/13 (92.3%) cases with newly diagnosed precursor-B-ALL, at least one triple-labeling per case at the level of 0.01% or more.
  • At the end of remission induction, the phenotypic aberrancies could be detected in 5/15 (33.3%), of which, 3/8 (37.5%) cases with the leukemic phenotypes detected both at the newly diagnosis and at the end of induction.
  • It is concluded that the flow cytometric detection of precursor-B-ALL-MRD proposed by BIOMED-1 Concerted Action were well realized in this study.
  • The one precursor-B-ALL cell can be effectively detected out of 10(4) normal bone marrow cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129033.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


53. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE: Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther; 2010 Jun;9(6):1872-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
  • The aims were to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit antitoxin antibody responses, and show that mutated drug was effective against systemic B-cell lymphoma in vivo.
  • Site-specific mutagenesis was used to mutate amino acids in seven key epitopic toxin regions that dictate B-cell generation of neutralizing antitoxin antibodies.
  • Finally, a powerful genetically altered luciferase xenograft model was used that could be imaged in real time to determine the effect on systemic malignant human B-cell lymphoma, Raji-luc.
  • Patient B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, and B lymphoma were high in CD22 and CD19 expression.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8548-53 [10890891.001]
  • [Cites] Cell. 1987 Mar 13;48(5):899-907 [3545499.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):995-1002 [11948105.001]
  • [Cites] Expert Opin Biol Ther. 2002 Dec;2(8):785-91 [12517258.001]
  • [Cites] Mol Cancer Ther. 2003 Dec;2(12):1341-50 [14707275.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1300-10 [4174339.001]
  • [Cites] Int J Cancer. 1978 Feb 15;21(2):166-70 [203546.001]
  • [Cites] Nature. 1989 Jun 1;339(6223):394-7 [2498664.001]
  • [Cites] Protein Eng. 1993 Nov;6(8):989-95 [8309948.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1329-36 [7509655.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1373-9 [8519647.001]
  • [Cites] Leukemia. 1996 Jun;10(6):937-42 [8667648.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1188-97 [8695836.001]
  • [Cites] J Cell Biol. 1996 Sep;134(6):1411-25 [8830771.001]
  • [Cites] Cell. 1997 Jul 25;90(2):335-49 [9244307.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2364-75 [9310487.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):968-75 [9500458.001]
  • [Cites] J Cell Biol. 1998 Nov 2;143(3):601-12 [9813083.001]
  • [Cites] Lancet. 1964 Feb 1;1(7327):238-40 [14086209.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):331-41 [15661270.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3879-88 [15897589.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8822-34 [17142785.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3058-67 [17505009.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6486-93 [17975161.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6 [18678888.001]
  • [Cites] Expert Opin Biol Ther. 2009 Jan;9(1):79-95 [19063695.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1233-42 [19327829.001]
  • [Cites] Br J Cancer. 2009 Oct 6;101(7):1114-23 [19755995.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6137-47 [19789305.001]
  • [Cites] Adv Drug Deliv Rev. 2009 Sep 30;61(11):977-85 [19679153.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):331-42 [19517064.001]
  • [Cites] EMBO J. 2009 Dec 2;28(23):3730-44 [19851281.001]
  • [Cites] Pancreas. 2010 Aug;39(6):913-22 [20182395.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] J Exp Med. 1986 Feb 1;163(2):347-68 [3511171.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • (PMID = 20530709.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108637; United States / NCI NIH HHS / CA / R01 CA082154; United States / NCI NIH HHS / CA / CA036725-25; United States / NCI NIH HHS / CA / CA108637-05; United States / NCI NIH HHS / CA / R01 CA036725; United States / NCI NIH HHS / CA / R01-CA36725; United States / NCI NIH HHS / CA / R01-CA082154; United States / NCI NIH HHS / CA / R01 CA108637-05; United States / NCI NIH HHS / CA / R01 CA036725-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, CD19; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Virulence Factors; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  • [Other-IDs] NLM/ NIHMS198461; NLM/ PMC2884080
  •  go-up   go-down


54. Campino S, Forton J, Auburn S, Fry A, Diakite M, Richardson A, Hull J, Jallow M, Sisay-Joof F, Pinder M, Molyneux ME, Taylor TE, Rockett K, Clark TG, Kwiatkowski DP: TLR9 polymorphisms in African populations: no association with severe malaria, but evidence of cis-variants acting on gene expression. Malar J; 2009 Mar 13;8:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, an association study of four common single nucleotide polymorphisms was performed on both family- and population-based studies from Malawian and Gambian populations (n>6000 individual).
  • For this work, an allele specific expression (ASE) assay on a panel of HapMap cell lines was carried out.
  • Using an allele specific expression assay it was observed that TLR9 expression is affected by cis-acting variants, these results were replicated in a second experiment using biological replicates.
  • This analysis considered all common variants in the region, but it is remains possible that there are rare variants with association signals.

  • Genetic Alliance. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jun 1;101(11):4500-4 [12560217.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e99 [17571926.001]
  • [Cites] Genet Epidemiol. 2004 Apr;26(3):186-205 [15022206.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):394-9 [15052269.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4926-33 [15067072.001]
  • [Cites] Nature. 2004 Aug 12;430(7001):743-7 [15269782.001]
  • [Cites] Science. 2004 Oct 22;306(5696):647-50 [15499010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):506-16 [8447318.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1399-404 [7723795.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):19-25 [15630134.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1217-24 [17873874.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1208-16 [17873875.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2496-503 [18250459.001]
  • [Cites] J Infect Dis. 2008 Sep 1;198(5):772-80 [18662133.001]
  • [Cites] Hum Hered. 2009;67(1):26-37 [18931507.001]
  • [Cites] PLoS One. 2008;3(12):e4105 [19116668.001]
  • [Cites] Anal Biochem. 2005 Apr 15;339(2):231-41 [15797563.001]
  • [Cites] Environ Microbiol. 2005 Jul;7(7):1024-8 [15946299.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1365-9 [16251966.001]
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3963-71 [16301213.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e78 [16362079.001]
  • [Cites] J Infect Dis. 2006 Jul 15;194(2):184-8 [16779724.001]
  • [Cites] Am J Hum Genet. 2006 Sep;79(3):539-43 [16909391.001]
  • [Cites] Genome Res. 2007 Jan;17(1):82-7 [17135570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1919-24 [17261807.001]
  • [Cites] J Commun Dis. 2006 Mar;38(3):230-45 [17373355.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):548-59 [17600128.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • (PMID = 19284650.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600230; United Kingdom / Medical Research Council / / G19/9; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toll-Like Receptor 9
  • [Other-IDs] NLM/ PMC2660361
  •  go-up   go-down


55. Takamori M, Motomura M, Fukudome T, Yoshikawa H: Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol; 2007 Nov;14(11):1230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lambert-Eaton myasthenic syndrome (LEMS), often associated with small-cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals.
  • In most patients, it is caused by autoantibodies against the P/Q-type voltage-gated calcium channels (VGCC) that trigger ACh release.
  • The M1-type pre-synaptic muscarinic ACh receptor (M1 mAChR) modulates cholinergic neuromuscular transmission by linking to P/Q-type VGCC, and may partially compensate for the reduced calcium entry.
  • (b) all five anti-VGCC-negative LEMS patients, one of whose serum had previously passively transferred LEMS-type electrophysiological defects to mice;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764462.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Receptor, Muscarinic M1
  •  go-up   go-down


56. Yang CY, Chen CC, Chen CY, Kuo HW: Air pollution and hospital admissions for asthma in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A; 2007 Jan 15;70(2):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Air pollution and hospital admissions for asthma in a subtropical city: Taipei, Taiwan.
  • This study was undertaken to determine whether there is an association between exposure to air pollutants levels and number of hospital admissions for asthma in Taipei, Taiwan.
  • Hospital admissions for asthma and ambient air pollution data for Taipei were obtained for the period from 1996 through 2003.
  • The relative risk of hospital admission for asthma was estimated using a case-crossover approach, controlling for weather variables, day of the week, seasonality, and long-term time trends.
  • In the single-air-pollutant model, on warm days (> or = 25 degrees C) statistically significant positive associations were found for SO2, NO2, and CO levels with an increase in asthmatic admissions.
  • On cool days (< 25 degrees C), all air pollutants were significantly associated with elevated asthma admissions except SO2.
  • For the two-air-pollutant model, CO significantly increases hospital admissions for asthma in combination with each of the other four pollutants on warm days.
  • On cool days, NO2 and O3 significantly elevated asthma rates in all the two-air-pollutant models.
  • This study provides evidence that higher levels of ambient air pollutant concentrations increase the risk of hospital admissions for asthma.
  • [MeSH-major] Air Pollutants / toxicity. Air Pollution / adverse effects. Asthma / epidemiology. Hospitalization / statistics & numerical data
  • [MeSH-minor] Carbon Monoxide / analysis. Carbon Monoxide / toxicity. Cities. Environmental Monitoring. Epidemiological Monitoring. Humans. Nitrogen Dioxide / analysis. Nitrogen Dioxide / toxicity. Ozone / analysis. Ozone / toxicity. Particulate Matter / analysis. Particulate Matter / toxicity. Sulfur Dioxide / analysis. Taiwan. Tropical Climate

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Air Pollution.
  • MedlinePlus Health Information. consumer health - Asthma.
  • Hazardous Substances Data Bank. OZONE .
  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • Hazardous Substances Data Bank. Carbon monoxide .
  • Hazardous Substances Data Bank. Sulfur dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365571.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Particulate Matter; 0UZA3422Q4 / Sulfur Dioxide; 66H7ZZK23N / Ozone; 7U1EE4V452 / Carbon Monoxide; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


57. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%.


58. Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, Matsunaga T, Inukai T, Goto H, Altura RA, Sugita K, Arisaka O, Look AT, Inaba T: Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. J Biol Chem; 2010 Jan 15;285(3):1850-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.
  • The E2A-HLF fusion transcription factor generated by t(17;19)(q22;p13) translocation is found in a small subset of pro-B cell acute lymphoblastic leukemias (ALLs) and promotes leukemogenesis by substituting for the antiapoptotic function of cytokines.
  • Forced expression of E2A-HLF in t(17;19)(-) leukemia cells up-regulated Survivin expression, suggesting that Survivin is a downstream target of E2A-HLF.
  • Analysis using a counterflow centrifugal elutriator revealed that t(17;19)+ ALL cells express Survivin throughout the cell cycle.
  • Reporter assays revealed that E2A-HLF induces survivin expression at the transcriptional level likely through indirect down-regulation of a cell cycle-dependent cis element in the promoter region.
  • Down-regulation of Survivin function by a dominant negative mutant of Survivin or reduction of Survivin expression induced massive apoptosis throughout the cell cycle in t(17;19)+ cells mainly through caspase-independent pathways involving translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus.
  • These data indicated that reversal of AIF translocation by Survivin, which is induced by E2A-HLF throughout the cell cycle, is one of the key mechanisms in the protection of t(17;19)+ leukemia cells from apoptosis.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Basic-Leucine Zipper Transcription Factors / metabolism. Microtubule-Associated Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Recombinant Fusion Proteins / metabolism. Translocation, Genetic / genetics. Up-Regulation
  • [MeSH-minor] Animals. Apoptosis. Base Sequence. Caspases / metabolism. Cell Cycle / genetics. Cell Line, Tumor. Cell Survival / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Humans. Inhibitor of Apoptosis Proteins. Mice. Molecular Sequence Data. Mutation. Precursor Cells, B-Lymphoid / cytology. Precursor Cells, B-Lymphoid / metabolism. Promoter Regions, Genetic / genetics. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Oct;2(4):279-88 [12398892.001]
  • [Cites] J Cell Biochem. 2008 Oct 1;105(2):381-90 [18553460.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):401-6 [12590264.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4266-80 [12833149.001]
  • [Cites] J Cell Physiol. 2003 Oct;197(1):8-29 [12942537.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4179-86 [12920030.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):39-48 [14712209.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3185-91 [15070701.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Science. 1992 Jul 24;257(5069):531-4 [1386162.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1608-20 [1516826.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3403-13 [8164688.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):266-75 [7835337.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1211-24 [8608207.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):541-4 [8700228.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):545-7 [8700229.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2609-14 [9122243.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:305-11 [10567210.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 17;93(20):1541-52 [11604477.001]
  • [Cites] Science. 2002 Jul 12;297(5579):259-63 [12114629.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3980-90 [9166836.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):6035-43 [9742120.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Blood. 1999 Jan 1;93(1):321-32 [9864177.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1457-62 [9990045.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2754-62 [10082541.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):309-19 [10518212.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):343-52 [10518215.001]
  • [Cites] Neoplasma. 2006;53(3):206-12 [16652189.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):264-72 [16621561.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):476-86 [16557517.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2247-56 [16728972.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4844-62 [17470554.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2439-47 [17600109.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] Tohoku J Exp Med. 2008 Sep;216(1):25-34 [18719335.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 19887369.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Basic-Leucine Zipper Transcription Factors; 0 / HLF protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Recombinant Fusion Proteins; 0 / TCF3 protein, human; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2804343
  •  go-up   go-down


59. Chutiwitoonchai N, Shen Y, Zheng H, Xiong H, Zhao G, Imtawil K, Intapan PM, Wongkham S, Wongkham C: Opisthorchis viverrini: Gene expression profiling of carcinogenic adult liver fluke worms using 5' SAGE. Exp Parasitol; 2008 Dec;120(4):306-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most abundant tag sequences were vitelline B precursor protein and myoglobin.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786530.001).
  • [ISSN] 1090-2449
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J: In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell; 2008 Jul 8;14(1):47-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.
  • We examined the leukemic stem cell potential of blasts at different stages of maturation in childhood acute lymphoblastic leukemia (ALL).
  • Cells sorted using the B precursor differentiation markers CD19, CD20, and CD34 were isolated from patient samples and engrafted mice before serial transplantation into primary or subsequent (up to quaternary) recipients.
  • Sorted blast populations mirrored normal B precursor cells with transcription of a number of stage-appropriate genes.
  • These observations inform a model for leukemia-propagating stem cells in childhood ALL.


61. Hill QA, Owen RG: CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev; 2006 Nov;20(6):319-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CNS relapse occurred in 30-50% of those with Burkitt lymphoma and acute lymphoblastic leukaemia/lymphoma prior to the introduction of intensified regimens that include CNS prophylaxis.
  • Most patients with AIDS-related-lymphoma receive a short course of intrathecal prophylaxis but a re-evaluation of type and targeting of CNS prophylaxis is needed.
  • Patients with diffuse large B-cell lymphoma (DLBCL) have a 5% overall risk of CNS relapse but a high risk sub-population can be identified on the basis of raised LDH and >1 extranodal site, testicular or primary breast involvement.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884838.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 151
  •  go-up   go-down


62. Feola DJ, Garvy BA: Zidovudine plus sulfamethoxazole-trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. Int Immunopharmacol; 2005 Dec;5(13-14):1881-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sulfamethoxazole-trimethoprim and zidovudine (AZT), drugs used often in combination in patients infected with HIV, were investigated for their effects on B cell development in a mouse model.
  • Immune cell populations in the spleen, lung, and peripheral blood were examined, and toxicity to B lineage subtypes in the bone marrow was investigated by phenotypic analysis via flow cytometry.
  • Pre-pro-B, pro-B, early pre-B, and late pre-B cells were assayed for apoptosis and analyzed for cell cycle profile.
  • Total as well as B cell splenic and bone marrow cellularities were significantly decreased by using the drugs concomitantly, while B cell populations in the lungs and percentage in the peripheral blood were not affected.
  • Combination therapy caused significant increases in apoptosis in B cells and granulocytes in the bone marrow, with the late pre-B cell population being the most depleted.
  • The proliferative expansion and differentiation of early pre-B cells (B220+/CD43+/BP-1+/HSA+) to the late pre-B cell (B220+/CD43-/IgM-) stage was blocked, with early pre-B cells accumulating in the proliferative phases of the cell cycle.
  • [MeSH-major] B-Lymphocyte Subsets / drug effects. Bone Marrow Cells / drug effects. Cell Differentiation / drug effects. Trimethoprim, Sulfamethoxazole Drug Combination / toxicity. Zidovudine / toxicity
  • [MeSH-minor] Animals. Anti-HIV Agents. Antigens, CD43 / analysis. Antigens, CD45 / analysis. Apoptosis / drug effects. Bone Marrow / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Granulocytes / drug effects. Immunophenotyping. Isoantigens / analysis. Mice. Mice, Inbred BALB C. Random Allocation. Spleen / cytology. Spleen / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275623.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL064524
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antigens, CD43; 0 / BP-1 alloantigen; 0 / Isoantigens; 4B9XT59T7S / Zidovudine; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


63. Cheng XW: 1-Acetyl-5,6-dimethoxy-indoline at 123 K. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 7):o1309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the title compound, C(12)H(15)NO(3), all C, N and O atoms lie in a mirror plane.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21202937.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2961829
  •  go-up   go-down


64. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med; 2005 Feb 17;352(7):666-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
  • BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (BNP) is a strong predictor of mortality among patients with acute coronary syndromes and may be a strong prognostic marker in patients with chronic coronary heart disease as well.
  • We assessed the relationship between N-terminal pro-BNP (NT-pro-BNP) levels and long-term mortality from all causes in a large cohort of patients with stable coronary heart disease.
  • METHODS: NT-pro-BNP was measured in baseline serum samples from 1034 patients referred for angiography because of symptoms or signs of coronary heart disease.
  • The median NT-pro-BNP level was significantly lower among patients who survived than among those who died (120 pg per milliliter [interquartile range, 50 to 318] vs. 386 pg per milliliter [interquartile range, 146 to 897], P<0.001).
  • Patients with NT-pro-BNP levels in the highest quartile were older, had a lower left ventricular ejection fraction (LVEF) and a lower creatinine clearance rate, and were more likely to have a history of myocardial infarction, clinically significant coronary artery disease, and diabetes than patients with NT-pro-BNP levels in the lowest quartile.
  • In a multivariable Cox regression model, the hazard ratio for death from any cause for the patients with NT-pro-BNP levels in the fourth quartile as compared with those in the first quartile was 2.4 (95 percent confidence interval, 1.5 to 4.0; P<0.001); the NT-pro-BNP level added prognostic information beyond that provided by conventional risk factors, including the patient's age; sex; family history with respect to ischemic heart disease; the presence or absence of a history of myocardial infarction, angina, hypertension, diabetes, or chronic heart failure; creatinine clearance rate; body-mass index; smoking status; plasma lipid levels; LVEF; and the presence or absence of clinically significant coronary artery disease on angiography.
  • CONCLUSIONS: NT-pro-BNP is a marker of long-term mortality in patients with stable coronary disease and provides prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction.

  • Genetic Alliance. consumer health - Heart Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 May 12;352(19):2025-6; author reply 2025-6 [15888707.001]
  • (PMID = 15716560.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


65. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr; 2006 Mar;19(3):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Severe coronary artery disease, N- terminal pro-B-type natriuretic peptide level, left atrial size, flow propagation velocity, mitral E/Ea ratio, pulmonary atrial reversal velocity, and pulmonary-mitral atrial wave duration predicted an increased LVFP.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500488.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R, Teixeira A, Arthaud M, Riou B, Boddaert J: Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care; 2006;10(3):R82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis.
  • INTRODUCTION: Our objectives were to determine the causes of acute respiratory failure (ARF) in elderly patients and to assess the accuracy of the initial diagnosis by the emergency physician, and that of the prognosis.
  • The main causes of ARF were cardiogenic pulmonary edema (43%), community-acquired pneumonia (35%), acute exacerbation of chronic respiratory disease (32%), pulmonary embolism (18%), and acute asthma (3%); 47% had more than two diagnoses.
  • A missed diagnosis in the emergency department was noted in 101 (20%) patients.
  • The accuracy of the diagnosis of the emergency physician ranged from 0.76 for cardiogenic pulmonary edema to 0.96 for asthma.
  • In a multivariate analysis, inappropriate initial treatment (odds ratio 2.83, p < 0.002), hypercapnia > 45 mmHg (odds ratio 2.79, p < 0.004), clearance of creatinine < 50 ml minute-1 (odds ratio 2.37, p < 0.013), elevated NT-pro-B-type natriuretic peptide or B-type natriuretic peptide (odds ratio 2.06, p < 0.046), and clinical signs of acute ventilatory failure (odds ratio 1.98, p < 0.047) were predictive of death.
  • [MeSH-major] Emergency Medical Services. Emergency Service, Hospital. Hospital Mortality. Respiratory Insufficiency / diagnosis. Respiratory Insufficiency / etiology
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Female. Humans. Male. Physicians. Prognosis. Prospective Studies. Pulmonary Edema / complications. Pulmonary Edema / diagnosis. Pulmonary Edema / mortality. Pulmonary Edema / therapy

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1982 Apr 17;1(8277):907-8 [6122122.001]
  • [Cites] Am J Epidemiol. 1982 Jan;115(1):92-106 [7055134.001]
  • [Cites] Eur Heart J. 1987 Sep;8(9):1007-14 [3665952.001]
  • [Cites] Arch Intern Med. 1988 Jan;148(1):173-6 [3337592.001]
  • [Cites] Arch Intern Med. 1989 Oct;149(10):2277-82 [2802893.001]
  • [Cites] Am J Med. 1991 Mar;90(3):353-9 [1825901.001]
  • [Cites] Ann Emerg Med. 1992 Jun;21(6):669-74 [1590605.001]
  • [Cites] J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A [8376698.001]
  • [Cites] J Gen Intern Med. 1993 Jul;8(7):383-92 [8410400.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77-121 [7582322.001]
  • [Cites] Arch Intern Med. 1997 Jul 14;157(13):1453-9 [9224224.001]
  • [Cites] J Am Geriatr Soc. 2005 Apr;53(4):643-8 [15817011.001]
  • [Cites] Anesthesiology. 2005 May;102(5):885-91 [15851872.001]
  • [Cites] J Intern Med. 2005 Jul;258(1):77-85 [15953135.001]
  • [Cites] J Gen Intern Med. 1986 Nov-Dec;1(6):386-93 [3794838.001]
  • [Cites] Ann Emerg Med. 1999 Nov;34(5):595-603 [10533006.001]
  • [Cites] J Am Coll Cardiol. 2000 May;35(6):1628-37 [10807470.001]
  • [Cites] Eur Heart J. 2000 Aug;21(16):1301-36 [10952823.001]
  • [Cites] Br J Gen Pract. 2000 Jul;50(456):559-63 [10954938.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):1066-78 [11049791.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Feb;56(2):M88-96 [11213282.001]
  • [Cites] J Am Coll Cardiol. 2001 Dec;38(7):2101-13 [11738322.001]
  • [Cites] Eur J Heart Fail. 2002 Jan;4(1):91-8 [11812669.001]
  • [Cites] Circulation. 2002 Jul 23;106(4):416-22 [12135939.001]
  • [Cites] Eur Heart J. 2003 Mar;24(5):442-63 [12633546.001]
  • [Cites] Eur Heart J. 2003 Mar;24(5):464-74 [12633547.001]
  • [Cites] N Engl J Med. 2004 Feb 12;350(7):647-54 [14960741.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Intensive Care Med. 2004 Apr;30(4):647-54 [14985964.001]
  • [Cites] Intensive Care Med. 2004 May;30(5):882-8 [14991092.001]
  • [Cites] Gerontologist. 1970 Spring;10(1):20-30 [5420677.001]
  • [Cites] Acta Med Scand. 1980;207(3):225-30 [7368988.001]
  • [Cites] Postgrad Med J. 1981 Jul;57(669):419-24 [7312736.001]
  • [CommentIn] Crit Care. 2006;10(4):151 [16887005.001]
  • (PMID = 16723034.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550946
  •  go-up   go-down


67. Moon H, Huh J, Cho MS, Chi H, Chung WS: A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology. Korean J Lab Med; 2007 Aug;27(4):253-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology.
  • The differential diagnosis of acute lymphoblastic leukemia (ALL) from other small round blue cell tumors in children is very important for proper treatment, but sometimes difficult.
  • CD45 is expressed on almost all-human leukocytes and not expressed on other small round blue cell tumors.
  • Moreover, CD19 is expressed on all stages of B lineage cells and loss of this antigen is very rare in precursor B-cell ALL.
  • The cytogenetic study showed normal karyotype but amplification of MLL (myeloid/lymphoid or mixed lineage leukemia) gene was suggestive in the fluorescent in situ hybridization.
  • The patient received the standard chemotherapy for acute lymphoblastic leukemia and reached complete remission.
  • [MeSH-major] Antigens, CD19 / analysis. Antigens, CD45 / analysis. Bone Marrow / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Child. Female. Humans. In Situ Hybridization

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094585.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


68. Meloni-Ehrig AM, Tirado CA, Chen K, Jahn J, Suchan S, Scheerle J, Crosby MG, Meany H, Seibel N, Leitenberg D, Heritage DW, Mowrey PN: Isolated del(14)(q21) in a case of precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Aug;161(1):82-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated del(14)(q21) in a case of precursor B-cell acute lymphoblastic leukemia.
  • We present a case of del(14)(q21) as a sole abnormality in a 4-year-old boy diagnosed with precursor B-cell acute lymphoblastic leukemia (pre-B ALL).
  • To our knowledge, this is the first case of isolated del(14)(q21) in pre-B ALL.
  • Both samples showed a del(14)(q21) as the only abnormality.
  • [MeSH-major] Chromosomes, Human, Pair 4 / genetics. Gene Deletion. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080963.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Immunoglobulin Heavy Chains; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


69. Hagler KT, Zori RT, Yuan CM, Gray BA, Moreb JS: Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells. Clin Adv Hematol Oncol; 2005 Jan;3(1):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells.
  • [MeSH-major] Antigens, CD19 / analysis. Burkitt Lymphoma / diagnosis. Hypereosinophilic Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Flow Cytometry. Humans. Immunomagnetic Separation. In Situ Hybridization, Fluorescence. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Adv Hematol Oncol. 2005 Jan;3(1):64-9 [16166970.001]
  • (PMID = 16166969.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19
  •  go-up   go-down


70. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJ, Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Küppers R, Montesinos-Rongen M, Nagel I, Pott C, Richter J, Román-Gómez J, Seifert M, Stein H, Suela J, Trümper L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R: A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One; 2009 Sep 11;4(9):e6986
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system.
  • In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation.
  • We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias.
  • Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression.
  • As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes--DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1--that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1832-6 [14512355.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):274-80 [12527896.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):3-11 [17489980.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2003;68:69-78 [15338605.001]
  • [Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):808-14 [17299390.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):39-45 [17970783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4844-9 [18353987.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cytokine. 2009 Jan;45(1):8-11 [19071030.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):250-9 [18565646.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):697-704 [18288404.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Pharmacogenet Genomics. 2009 Feb;19(2):95-102 [18987561.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):1-13 [16426940.001]
  • [Cites] Ann Hematol. 2005 Apr;84(4):236-44 [15538567.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):285-90 [16126303.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2795-804 [19168792.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):137-44 [16846474.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Curr Opin Oncol. 2008 Nov;20(6):705-10 [18841054.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6118-28 [16778185.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):137-52 [15064862.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Eur J Immunol. 2004 Jul;34(7):1870-81 [15214035.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Leukemia. 2001 Apr;15(4):583-9 [11368360.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):758-64 [19155300.001]
  • [Cites] PLoS One. 2008;3(3):e1882 [18365023.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):237-42 [18176563.001]
  • [Cites] J Clin Gastroenterol. 2009 Feb;43(2):152-6 [18779738.001]
  • [Cites] Bioinformation. 2007 Apr 10;1(10):420-2 [17597932.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8123-30 [16912190.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2153-63 [17713554.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):1037-43 [18798072.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] J Immunol. 2001 May 15;166(10):5925-34 [11342607.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1824-31 [14512354.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1315-25 [18832655.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):124-31 [12496962.001]
  • [Cites] Mod Pathol. 2008 May;21(5):632-8 [18264085.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2031-2 [19021042.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):821-32 [18273643.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1855-62 [16900213.001]
  • [Cites] Leukemia. 2008 May;22(5):1035-43 [18288132.001]
  • [Cites] Oncogene. 2005 Oct 13;24(45):6848-54 [16007172.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):997-1007 [15746151.001]
  • (PMID = 19750229.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2737286
  •  go-up   go-down


71. Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, Davis RS: Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol; 2006 Nov 15;177(10):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two members of the recently identified FcR homolog (FcRH) family in mice demonstrate preferential B cell expression.
  • One of these, FcRH3, encodes a type I transmembrane protein with five extracellular Ig domains and a cytoplasmic tail with a consensus ITIM and a noncanonical ITAM.
  • A panel of FcRH3-specific mAbs was generated to define its expression pattern and functional potential on B lineage cells.
  • Although poorly detected on the majority of bone marrow or peripheral blood cells, FcRH3 was readily identified on splenic marginal zone (MZ) and MZ precursor B cells, but not on the bulk of newly formed B cells, follicular B cells, germinal center B cells, and plasma cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082595.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI014782; United States / NIAID NIH HHS / AI / AI14782; United States / NCI NIH HHS / CA / CA13148; United States / NIAID NIH HHS / AI / K08 AI55638
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / FcRH3 protein, mouse; 0 / Immunoglobulin Allotypes; 0 / Immunologic Factors; 0 / Receptors, Fc
  •  go-up   go-down


72. Matsuda R, Nikaido Y, Yamada T, Mishima H, Tamaki R: [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia]. No Shinkei Geka; 2005 Mar;33(3):277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia].
  • A 12 year-old girl was treated with prophylatic cranial irradiation for acute lymphoblastic leukaemia (ALL).
  • After surgery, this patient presented meningiomas which histologically, were of the meningothelial type.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773318.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


73. Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, Sahakian E, Kagoda M, Huang G, Hao QL, Sevilla Y, Barsky LW, Zielinska E, Price MA, Wall NR, Dovat S, Payne KJ: IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol; 2009 Apr 1;182(7):4255-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-7 is critical for B cell production in adult mice; however, its role in human B lymphopoiesis is controversial.
  • Here, we examine the role of IL-7 in human B cell development using a novel, human-only model based on coculturing human HSCs on primary human BM stroma.
  • In this model, IL-7 increases human B cell production by >60-fold from both CB and adult BM HSCs.
  • IL-7-induced increases are dose-dependent and specific to CD19(+) cells.
  • STAT5 phosphorylation and expression of the Ki-67 proliferation Ag indicate that IL-7 acts directly on CD19(+) cells to increase proliferation at the CD34(+) and CD34(-) pro-B cell stages.
  • Without IL-7, HSCs in CB, but not BM, give rise to a small but consistent population of CD19(lo) B lineage cells that express EBF (early B cell factor) and PAX-5 and respond to subsequent IL-7 stimulation.
  • As compared with CB, adult BM shows a reduction of in vitro generative capacity that is progressively more profound in developmentally sequential populations, resulting in an approximately 50-fold reduction in IL-7-dependent B lineage generative capacity.
  • These data provide evidence that IL-7 is essential for human B cell production from adult BM and that IL-7-induced expansion of the pro-B compartment is increasingly critical for human B cell production during the progression of ontogeny.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 1;94(11):3781-90 [10572092.001]
  • [Cites] Blood. 1997 May 15;89(10):3554-64 [9160660.001]
  • [Cites] Blood. 2000 Jul 1;96(1):9-23 [10891425.001]
  • [Cites] Immunol Rev. 2000 Jun;175:175-86 [10933602.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2382-9 [10946261.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2803-7 [11023514.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3683-90 [11389003.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] Leukemia. 2002 Mar;16(3):352-61 [11896538.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3091-8 [12626565.001]
  • [Cites] Int J Hematol. 2003 May;77(4):399-407 [12774932.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):773-9 [12872121.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1495-506 [14610045.001]
  • [Cites] J Immunol. 1987 Feb 15;138(4):1082-7 [3492541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):302-6 [2643102.001]
  • [Cites] J Immunol. 1989 Jun 1;142(11):3875-83 [2785567.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2229-38 [1718491.001]
  • [Cites] J Immunol. 1991 Nov 15;147(10):3324-30 [1719075.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1170-8 [7680240.001]
  • [Cites] Cell. 1993 Apr 9;73(1):147-57 [8462096.001]
  • [Cites] J Exp Med. 1993 Jul 1;178(1):113-20 [7686210.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):138-48 [7686930.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2396-405 [7691259.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5382-6 [8202495.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):58-67 [7527823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):377-81 [7831294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1570-4 [7533295.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1519-26 [7699333.001]
  • [Cites] Immunity. 1995 Apr;2(4):331-9 [7719938.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):855-64 [9541580.001]
  • [Cites] Protein Eng. 1998 Jan;11(1):31-40 [9579657.001]
  • [Cites] Leukemia. 1998 May;12(5):764-71 [9593276.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4145-51 [9596660.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):394-7 [9843216.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4509-20 [9845515.001]
  • [Cites] Blood. 1999 Jan 1;93(1):96-106 [9864151.001]
  • [Cites] Exp Hematol. 1999 Aug;27(8):1271-81 [10428504.001]
  • [Cites] Immunity. 1999 Jul;11(1):21-31 [10435576.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):971-9 [15767371.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1197-203 [15837809.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):203-9 [15867576.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):852-60 [15917481.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7325-31 [16301638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1000-5 [16418296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2262-7 [16461915.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):56-66 [16337808.001]
  • [Cites] Exp Hematol. 2006 Sep;34(9):1133-42 [16939806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17852-7 [17090683.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2086-8 [17053062.001]
  • [Cites] Adv Exp Med Biol. 2007;596:57-62 [17338175.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):1068-79 [17617599.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1398-407 [17656007.001]
  • [Cites] BMC Biol. 2007;5:36 [17854505.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):383-92 [18566404.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2297-304 [18566323.001]
  • [Cites] Nature. 1995 Sep 7;377(6544):65-8 [7659163.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 29;764:9-18 [7486595.001]
  • [Cites] Blood. 1996 May 1;87(9):3563-70 [8611678.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1881-90 [8634436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10348-53 [8816803.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):66-72 [8989909.001]
  • [Cites] Blood. 1997 Feb 1;89(3):929-40 [9028324.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1167-76 [10642804.001]
  • (PMID = 19299724.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD001632; United States / NIDDK NIH HHS / DK / 5K01 DK066163; United States / NIDDK NIH HHS / DK / DK066163-06; United States / NIMHD NIH HHS / MD / P20 MD006988; United States / NIDDK NIH HHS / DK / DK066163-02; United States / NIDDK NIH HHS / DK / K01 DK066163-05; United States / NCI NIH HHS / CA / K22 CA111392; United States / NIDDK NIH HHS / DK / DK066163-04; United States / NIDDK NIH HHS / DK / K01 DK066163-01; United States / NIDDK NIH HHS / DK / K01 DK066163-06; United States / NIDDK NIH HHS / DK / DK066163-03; United States / NIMHD NIH HHS / MD / P20 MD001632-02; United States / NIGMS NIH HHS / GM / R25 GM060507; United States / NIGMS NIH HHS / GM / R25 GM060507-02; United States / NIDDK NIH HHS / DK / K01 DK066163-02; United States / NIDDK NIH HHS / DK / K01 DK066163-04; United States / NIDDK NIH HHS / DK / DK066163-01; United States / NIDDK NIH HHS / DK / K01 DK066163; United States / NIDDK NIH HHS / DK / K01 DK066163-03; United States / NIDDK NIH HHS / DK / DK066163-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-7
  • [Other-IDs] NLM/ NIHMS95094; NLM/ PMC2659466
  •  go-up   go-down


74. Kempf T, Wollert KC: Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz; 2009 Dec;34(8):594-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated circulating levels of GDF-15 identify high-risk individuals across the cardiovascular continuum, from stable coronary artery disease to acute coronary syndrome and heart failure.
  • The association of GDF-15 with outcome in these conditions is independent of clinical risk factors and established biomarkers, including NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin.
  • The prognostic information provided by GDF-15 in cardiovascular disease may inform patient management, e.g., by identifying patients with non-ST segment elevation acute coronary syndrome who benefit from an invasive strategy, or by monitoring treatment response in heart failure.
  • [MeSH-major] Cardiovascular Diseases / blood. Cardiovascular Diseases / diagnosis. Growth Differentiation Factor 15 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):253-62 [18164124.001]
  • [Cites] J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60 [17825714.001]
  • [Cites] Circulation. 2007 Oct 2;116(14):1540-8 [17848615.001]
  • [Cites] Eur J Heart Fail. 2008 Sep;10(9):824-39 [18760965.001]
  • [Cites] Circ Res. 2006 Feb 17;98(3):351-60 [16397141.001]
  • [Cites] Herz. 2008 Mar;33(2):115-21 [18344030.001]
  • [Cites] Eur Heart J. 2008 Oct;29(19):2327-35 [18664460.001]
  • [Cites] Endocrinology. 2009 Apr;150(4):1688-96 [19074584.001]
  • [Cites] Cardiovasc Res. 2008 Jul 15;79(2):294-303 [18359786.001]
  • [Cites] Eur Heart J. 2007 Dec;28(23):2858-65 [17977844.001]
  • [Cites] Circ Cardiovasc Genet. 2009 Jun;2(3):286-92 [20031597.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):226-32 [10413734.001]
  • [Cites] Herz. 2009 Mar;34(2):141-7 [19370331.001]
  • [Cites] Eur Heart J. 2009 Nov;30(22):2749-57 [19666898.001]
  • [Cites] Cell Tissue Res. 2004 Nov;318(2):325-33 [15459768.001]
  • [Cites] Arthritis Rheum. 2007 Mar;56(3):753-64 [17328047.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):2007-18 [12748317.001]
  • [Cites] Circulation. 2007 Feb 27;115(8):949-52 [17325253.001]
  • [Cites] Hypertension. 2008 Feb;51(2):309-18 [18158353.001]
  • [Cites] Circ Res. 2007 Jan 5;100(1):61-9 [17138942.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4610-9 [15958647.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 1;178(5):534-41 [18565955.001]
  • [Cites] Clin Chem. 2007 Feb;53(2):284-91 [17185363.001]
  • [Cites] Am J Respir Crit Care Med. 2008 May 1;177(9):1018-25 [18263797.001]
  • [Cites] Eur Heart J. 2009 Oct;30(19):2346-53 [19561023.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2148-59 [18480207.001]
  • [Cites] Circ Res. 2006 Feb 17;98(3):342-50 [16397142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9 [9326641.001]
  • [Cites] Circulation. 2007 Nov 27;116(22):2634-53 [17951284.001]
  • [Cites] Circulation. 2007 Feb 27;115(8):962-71 [17283261.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):4983-6 [16707416.001]
  • (PMID = 20024638.001).
  • [ISSN] 1615-6692
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Growth Differentiation Factor 15
  •  go-up   go-down


75. Fistonić I, Canić T, Duić Z, Fistonić M, Ciglar S: [Alternative hormone therapy in postmenopause]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the fact that hormonal combination used in huge Wpmen's Health Initiative (WHI) is not common all over the world, and treated population is, because of age, in risk per se, study results have consternated not only lay users, but prescribers too.
  • This review shows not only mandatory list of possibilities, but also emphasises which of the alternative and complementary treatments are evidence based regarding published randomized controlled trials.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lijec Vjesn. 2006 Jul-Aug;128(7-8):252; author reply 252-3 [17087144.001]
  • (PMID = 16808100.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 80
  •  go-up   go-down


76. Matsusaka S, Tohyama Y, He J, Shi Y, Hazama R, Kadono T, Kurihara R, Tohyama K, Yamamura H: Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochem Biophys Res Commun; 2005 Mar 25;328(4):1163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell polarization and migration in response to CXCL12 is essential for hematopoiesis.
  • To investigate the role of Syk in CXCL12/CXCR4-induced signaling, wild-type Syk or its dominant-negative form (DN-Syk) was introduced in mouse pro-B cells, BAF3.
  • Overexpression of wild-type Syk caused enhanced polarization, whereas DN-Syk inhibited cell polarity due to the loss of contractile structure at the rear end, and the altered phenotype was enhanced after CXCL12 stimulation.
  • As beta1 integrin-mediated cell adhesion was inhibited, decreased adhesion might promote motility.
  • These results demonstrate that Syk participates in CXCL12-induced cell polarization, which occurs in concert with cell adhesion mediated by beta1 integrin.
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Movement / drug effects. Cell Movement / physiology. Cell Polarity / drug effects. Cell Polarity / physiology. Cells, Cultured. Chemokine CXCL12. Dose-Response Relationship, Drug. Intracellular Signaling Peptides and Proteins. Mice. Recombinant Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707999.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Enzyme Precursors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Recombinant Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase
  •  go-up   go-down


77. Minami A, Tsuboi I, Harada T, Fukumoto T, Hiramoto M, Koshinaga M, Hirabayashi Y, Kanno J, Inoue T, Aizawa S: Inflammatory biomarker, neopterin, suppresses B lymphopoiesis for possible facilitation of granulocyte responses, which is severely altered in age-related stromal-cell-impaired mice, SCI/SAM. Exp Biol Med (Maywood); 2007 Jan;232(1):134-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory biomarker, neopterin, suppresses B lymphopoiesis for possible facilitation of granulocyte responses, which is severely altered in age-related stromal-cell-impaired mice, SCI/SAM.
  • We found that neopterin enhanced in vivo and in vitro granulopoiesis triggered by the stromal-cell production of cytokines in mice.
  • The effects of neopterin on B lymphopoiesis during the enhancement of granulopoiesis were determined using the mouse model of senescent stromal-cell impairment (SCI), a subline of senescence-accelerated mice (SAM).
  • In non-SCI mice (a less senescent stage of SCI mice), treatment with neopterin decreased the number of colonies, on a semisolid medium, of colony-forming units of pre-B-cell progenitors (CFU-preB) from unfractionated bone marrow (BM) cells, but not that from a population rich in pro-B and pre-B cells without stromal cells.
  • Neopterin upregulated the expression of genes for the negative regulators of B lymphopoiesis such as tumor necrosis factor-alpha (TNF-alpha ), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-beta) in cultured stromal cells, implying that neopterin suppressed the CFU-preB colony formation by inducing negative regulators from stromal cells.
  • The intraperitoneal injection of neopterin into non-SCI mice resulted in a marked decrease in the number of femoral CFU-preB within 1 day, along with increases in TNF-alpha and IL-6 expression levels.
  • These results also suggest that neopterin facilitated granulopoiesis in BM by suppressing B lymphopoiesis, thereby contributing to the potentiation of the inflammatory process; interestingly, such neopterin function became impaired during senescence because of attenuated stromal-cell function, resulting in the downmodulation of the host-defense mechanism in the aged.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202594.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 670-65-5 / Neopterin
  •  go-up   go-down


78. Szopa M, Meirhaeghe A, Luan J, Moreno LA, Gonzalez-Gross M, Vidal-Puig A, Cooper C, Hagen R, Amouyel P, Wareham NJ, Loos RJ: No association between polymorphisms in the INSIG1 gene and the risk of type 2 diabetes and related traits. Am J Clin Nutr; 2010 Jul;92(1):252-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between polymorphisms in the INSIG1 gene and the risk of type 2 diabetes and related traits.
  • OBJECTIVE: We tested for associations between 6 INSIG1 tag single nucleotide polymorphisms (SNPs) (and captured all common variations in INSIG1) and the risk of type 2 diabetes (T2D), obesity, and related traits in 10,567 adults and 1155 adolescents from 5 population-based studies, a T2D case-control study, and a T2D case-series.
  • CONCLUSION: Although our study was sufficiently powered to identify small effects, the results suggest that common variation in INSIG1 is unlikely to have a major effect on T2D and obesity risk and related traits in white Europeans.
  • [MeSH-major] Diabetes Mellitus, Type 2 / genetics. Intracellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Obesity / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444954.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0802051; United Kingdom / Medical Research Council / / MC/ UP/ A620/ 1014; United Kingdom / Medical Research Council / / MC/ U106179471; United Kingdom / Medical Research Council / / MC/ U106188470; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / INSIG1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins
  •  go-up   go-down


79. Scott NE, Bogema DR, Connolly AM, Falconer L, Djordjevic SP, Cordwell SJ: Mass spectrometric characterization of the surface-associated 42 kDa lipoprotein JlpA as a glycosylated antigen in strains of Campylobacter jejuni. J Proteome Res; 2009 Oct;8(10):4654-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Campylobacter jejuni is the most common cause of bacterial gastroenteritis in the developed world.
  • Immunoproteomics highlighted a 42-45 kDa antigen that comigrated on two-dimensional (2-DE) gels with the C. jejuni major outer membrane protein (MOMP).
  • Soybean agglutinin affinity and 2-DE purified 2 JlpA glycoforms (43.5 and 45 kDa).
  • Sequence analysis confirmed that the N146 sequon is conserved in all C. jejuni genomes examined to date, while the N107 sequon is absent in the reference strain NCTC 11168.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689120.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Outer Membrane Proteins; 0 / Lipoproteins; 0 / Peptide Fragments; 0 / Plant Lectins; 0 / Recombinant Proteins; 0 / Soybean Proteins; 0 / soybean lectin
  •  go-up   go-down


80. Grodzki AC, Berenstein E: Introduction to the purification of antibodies. Methods Mol Biol; 2010;588:11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The availability of commercially available kits primarily designed for the purification of IgG and IgM classes of antibodies derived from all common animal species should also be mentioned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012813.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


81. Goios A, Pereira L, Bogue M, Macaulay V, Amorim A: mtDNA phylogeny and evolution of laboratory mouse strains. Genome Res; 2007 Mar;17(3):293-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By a phylogenetic analysis of newly generated complete mitochondrial DNA sequence data in 16 strains, we show here that all common inbred strains descend from the same Mus musculus domesticus female wild ancestor, and suggest that they present a different mitochondrial evolutionary process than their wild relatives with a faster accumulation of replacement substitutions.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • Mouse Phenome Database (MPD). Related data set (IPATIMUP1) available .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Jan;24(1):23-5 [10615122.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1261-8 [17013393.001]
  • [Cites] J Hered. 2001 Jul-Aug;92(4):352-5 [11535650.001]
  • [Cites] Hum Mol Genet. 2001 Oct 15;10(22):2469-79 [11709534.001]
  • [Cites] Mutat Res. 2002 Apr 25;501(1-2):19-28 [11934434.001]
  • [Cites] Mol Phylogenet Evol. 2002 May;23(2):123-36 [12069545.001]
  • [Cites] Syst Biol. 2002 Jun;51(3):410-31 [12079642.001]
  • [Cites] Lancet. 2002 Oct 26;360(9342):1323-5 [12414225.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):574-8 [12466852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):171-6 [12509511.001]
  • [Cites] Am J Hum Genet. 2003 Mar;72(3):659-70 [12571803.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):519-29 [12729587.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3497-500 [12824352.001]
  • [Cites] Nucleic Acids Res. 2003 Sep 15;31(18):5349-55 [12954771.001]
  • [Cites] J Appl Physiol (1985). 2003 Oct;95(4):1335-7 [12970372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1685-90 [14745024.001]
  • [Cites] Genetics. 1981 Aug;98(4):801-16 [6277733.001]
  • [Cites] Differentiation. 1982;22(3):222-6 [6293902.001]
  • [Cites] Nature. 1985 May 2-8;315(6014):70-2 [2986012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):4992-5 [2740336.001]
  • [Cites] Cell. 1990 Mar 23;60(6):971-80 [2317868.001]
  • [Cites] Genetics. 1995 Oct;141(2):743-53 [8647407.001]
  • [Cites] Exp Gerontol. 1997 Jan-Apr;32(1-2):105-9 [9088907.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Science. 1999 Mar 5;283(5407):1482-8 [10066162.001]
  • [Cites] Mol Phylogenet Evol. 2004 Dec;33(3):626-46 [15522792.001]
  • [Cites] Nature. 2004 Nov 4;432(7013):5 [15525947.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D471-5 [15608240.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Feb 25;327(4):1028-35 [15652499.001]
  • [Cites] Mamm Genome. 2005 Jan;16(1):11-9 [15674729.001]
  • [Cites] Mol Biol Evol. 2005 Jul;22(7):1561-8 [15814826.001]
  • [Cites] BMC Cancer. 2005;5:102 [16105171.001]
  • [Cites] Trends Genet. 2006 Feb;22(2):79-83 [16356585.001]
  • [Cites] ILAR J. 2006;47(2):94-102 [16547366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14461-6 [11106380.001]
  • (PMID = 17284675.001).
  • [ISSN] 1088-9051
  • [Journal-full-title] Genome research
  • [ISO-abbreviation] Genome Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC1800920
  •  go-up   go-down


82. Yang J, Zhou X, Wang B, Gao C, Zhang RD, Li B: [Severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene: report of two cases and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Sep;30(9):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene: report of two cases and literature review].
  • OBJECTIVE: To improve the understanding of severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene, and to explore the mechanism of pathogenesis and the relationship between the special gene translocation and severe hypercalcemia.
  • RESULTS: Two patients with E2A-HLF fusion gene, which is generated by t(17;19) (q22, p13) translocation, suffered relapse of leukemia three months after chemotherapy, and developed severe hypercalcemia.
  • In B cell lymphoblastic leukemia with E2A-HLF fusion gene, the fusion gene showed be closely monitored for evaluating the disease situation.
  • [MeSH-major] DNA-Binding Proteins / genetics. Hypercalcemia / etiology. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954622.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / E2a-Hlf fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


83. Kosuge K, Soma M, Nakayama T, Aoi N, Sato M, Izumi Y, Matsumoto K: A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5'-flanking region is associated with essential hypertension among Japanese females. Int J Med Sci; 2007;4(3):146-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5'-flanking region is associated with essential hypertension among Japanese females.
  • The present study identified variants in the 5'-flanking region of natriuretic peptide precursor B (NPPB) gene and assessed the relationship between gene variants and EH.

  • Genetic Alliance. consumer health - Essential hypertension.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):345-9 [11386007.001]
  • [Cites] Am J Hypertens. 2000 Dec;13(12):1263-7 [11130769.001]
  • [Cites] Endocrine. 2002 Mar;17(2):85-90 [12041919.001]
  • [Cites] Hypertens Res. 2002 May;25(3):395-401 [12135318.001]
  • [Cites] J Am Coll Cardiol. 2002 Sep 4;40(5):976-82 [12225726.001]
  • [Cites] Hypertension. 2003 Apr;41(4):978-83 [12623868.001]
  • [Cites] Circulation. 2004 Feb 10;109(5):594-600 [14769680.001]
  • [Cites] Hypertens Res. 2004 Apr;27(4):235-41 [15127880.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Jan 13;118(1):131-9 [6230082.001]
  • [Cites] Nature. 1988 Mar 3;332(6159):78-81 [2964562.001]
  • [Cites] Lancet. 1990 Mar 31;335(8692):801-2 [1969551.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Apr 30;168(2):863-70 [2139780.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):1145-9 [1522222.001]
  • [Cites] Cell. 1992 Oct 2;71(1):169-80 [1394429.001]
  • [Cites] J Hypertens. 1992 Sep;10(9):907-12 [1328371.001]
  • [Cites] J Clin Invest. 1994 May;93(5):1911-21 [8182124.001]
  • [Cites] J Mol Med (Berl). 1995 Sep;73(9):457-63 [8528749.001]
  • [Cites] Lancet. 1996 Mar 16;347(9003):731-3 [8602004.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):736-9 [9618281.001]
  • [Cites] J Hum Genet. 1998;43(3):149-52 [9747025.001]
  • [Cites] Circ Res. 1999 Mar 19;84(5):605-10 [10082481.001]
  • [Cites] Am J Hypertens. 2004 Nov;17(11 Pt 1):1045-9 [15533732.001]
  • [Cites] J Hum Hypertens. 2005 Feb;19(2):165-72 [15496965.001]
  • [Cites] Hypertens Res. 2004 Oct;27(10):711-6 [15785005.001]
  • [Cites] Am J Hypertens. 2005 Mar;18(3):403-8 [15797661.001]
  • [Cites] Am J Hypertens. 2006 Jun;19(6):593-600 [16733231.001]
  • [Cites] Am J Hypertens. 2007 May;20(5):527-32 [17485015.001]
  • [Cites] Am J Hypertens. 1999 Nov;12(11 Pt 1):1144-8 [10604494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4239-44 [10737768.001]
  • [Cites] Circ Res. 2000 Apr 28;86(8):841-5 [10785505.001]
  • [Cites] Clin Sci (Lond). 2001 Nov;101(5):447-53 [11672449.001]
  • (PMID = 17554401.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 114471-18-0 / Natriuretic Peptide, Brain
  • [Other-IDs] NLM/ PMC1885554
  •  go-up   go-down


84. Benne C, Lelievre JD, Balbo M, Henry A, Sakano S, Levy Y: Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage. Stem Cells; 2009 Jul;27(7):1676-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage.
  • Notch and its ligands regulate multiple cell fate decisions.
  • Here, we used recombinant Delta ligands to deliver temporally and dose-controlled signals to human immature cord blood CD34(+)CD38(low) cells at clonal cell levels.
  • Notch activation increased the frequency of multipotent progenitors, skewed the T and natural killer (NK) cell potential of CD34(+)CD38(low) clones in a dose- and ligand-dependent manner, and inhibited the differentiation of B cell clones.
  • Low doses of ligands were sufficient for significantly increasing the frequency of NK cell precursors, whereas higher doses were required for increasing the frequency of T-cell clones.
  • Interestingly, we demonstrate that temporary Notch activation prevents the subsequent differentiation of CD34(+)CD38(low) cells beyond a pro-B CD79a(+)CD19(-) stage characterized as a common lymphoid progenitor (CLP).
  • Moreover, the lymphoid potential of this pro-B/CLP was skewed toward NK cell potential while the B cell precursor frequency was dramatically reduced.
  • These results may have implications both in physiology and for cell manipulation because they demonstrate a tight regulation of the fate of human progenitors by Notch signaling.
  • [MeSH-minor] Animals. Antigens, CD34 / immunology. Antigens, CD38 / metabolism. Cell Cycle / genetics. Cell Cycle / physiology. Cell Differentiation / drug effects. Cell Line. Cells, Cultured. Fetal Blood / cytology. Flow Cytometry. Humans. Intracellular Signaling Peptides and Proteins. Membrane Proteins / pharmacology. Mice. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544442.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Receptors, Notch; 0 / delta protein; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


85. Welker NC, Pavelec DM, Nix DA, Duchaine TF, Kennedy S, Bass BL: Dicer's helicase domain is required for accumulation of some, but not all, C. elegans endogenous siRNAs. RNA; 2010 May;16(5):893-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparisons of wild-type and helicase-defective strains using deep-sequencing analyses show that the helicase domain is required by a subset of annotated endo-siRNAs, in particular, those associated with the slightly longer 26-nucleotide small RNA species containing a 5' guanosine.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Nov 1;21(21):5875-85 [12411505.001]
  • [Cites] J Mol Biol. 2008 Jun 27;380(1):237-43 [18508075.001]
  • [Cites] Mol Cell. 2008 Jul 11;31(1):79-90 [18571451.001]
  • [Cites] Mol Cell. 2008 Jul 11;31(1):67-78 [18571452.001]
  • [Cites] Mol Cell. 2008 Aug 8;31(3):309-12 [18691963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12897-902 [18723671.001]
  • [Cites] PLoS One. 2008;3(12):e4052 [19112503.001]
  • [Cites] BMC Bioinformatics. 2008;9:523 [19061503.001]
  • [Cites] Cell. 2009 Feb 20;136(4):642-55 [19239886.001]
  • [Cites] Mol Cell. 2009 Oct 23;36(2):231-44 [19800275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18674-9 [19846761.001]
  • [Cites] Genetics. 2009 Dec;183(4):1283-95 [19797044.001]
  • [Cites] Annu Rev Biophys. 2008;37:317-36 [18573084.001]
  • [Cites] BMC Genomics. 2008;9:270 [18522735.001]
  • [Cites] Cell. 1999 Oct 15;99(2):123-32 [10535731.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):325-30 [11099033.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):363-6 [11201747.001]
  • [Cites] Gene. 2001 Jan 24;263(1-2):103-12 [11223248.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2269-71 [11486053.001]
  • [Cites] Genes Dev. 2001 Oct 15;15(20):2654-9 [11641272.001]
  • [Cites] Curr Biol. 2002 Aug 6;12(15):1317-9 [12176360.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • [Cites] Curr Biol. 2003 May 13;13(10):807-18 [12747828.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):845-9 [14685240.001]
  • [Cites] Cell. 2004 Apr 2;117(1):69-81 [15066283.001]
  • [Cites] Cell. 2004 Jul 9;118(1):57-68 [15242644.001]
  • [Cites] Genetics. 1997 May;146(1):227-38 [9136012.001]
  • [Cites] J Virol. 1997 Dec;71(12):9400-9 [9371600.001]
  • [Cites] Science. 2006 Jan 13;311(5758):195-8 [16410517.001]
  • [Cites] Cell. 2006 Jan 27;124(2):343-54 [16439208.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] RNA. 2006 Apr;12(4):589-97 [16489184.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):3465-75 [16849434.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1193-207 [17174894.001]
  • [Cites] Science. 2007 Jan 12;315(5809):241-4 [17124291.001]
  • [Cites] Science. 2007 Jan 12;315(5809):244-7 [17158288.001]
  • [Cites] Curr Opin Struct Biol. 2007 Feb;17(1):138-45 [17194582.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):e60 [17405769.001]
  • [Cites] Annu Rev Biochem. 2007;76:23-50 [17506634.001]
  • [Cites] Nat Struct Mol Biol. 2007 Jul;14(7):604-10 [17603500.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):449-61 [17658285.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28373-8 [17666393.001]
  • [Cites] EMBO J. 2007 Dec 12;26(24):5007-19 [18007599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):391-401 [18414490.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):581-90 [18500351.001]
  • [Cites] Nature. 2008 Jun 5;453(7196):798-802 [18463631.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):231-7 [12529635.001]
  • (PMID = 20354150.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM067106-06; United States / NIGMS NIH HHS / GM / GM067106; United States / NIGMS NIH HHS / GM / R01 GM067106-06; United States / NCI NIH HHS / CA / CA04214; United States / NIGMS NIH HHS / GM / R01 GM076619; United States / NIGMS NIH HHS / GM / GM076619; United States / NIGMS NIH HHS / GM / R01 GM067106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Helminth; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / RNA Helicases
  • [Other-IDs] NLM/ PMC2856884
  •  go-up   go-down


86. Masek BJ, Arora N, Quinn N, Aumakhan B, Holden J, Hardick A, Agreda P, Barnes M, Gaydos CA: Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program. J Clin Microbiol; 2009 Jun;47(6):1663-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All C. trachomatis and N. gonorrhoeae Combo2-positive/ProbeTec-negative samples were confirmed as true positives by an alternative NAAT.

  • Genetic Alliance. consumer health - Chlamydia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):386-90 [9889224.001]
  • [Cites] J Clin Microbiol. 1998 Feb;36(2):375-81 [9466744.001]
  • [Cites] Infect Dis Clin North Am. 2005 Jun;19(2):367-86, ix [15963877.001]
  • [Cites] Sex Transm Dis. 2005 Dec;32(12):725-8 [16314767.001]
  • [Cites] Sex Transm Dis. 2005 Dec;32(12):729-33 [16314768.001]
  • [Cites] Sex Transm Dis. 2006 Jul;33(7):451-7 [16652069.001]
  • [Cites] Sex Health. 2006 Dec;3(4):209-15 [17112429.001]
  • [Cites] Sex Transm Infect. 2006 Dec;82(6):425-30 [17151028.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):292-303 [17050567.001]
  • [Cites] Sex Transm Dis. 2008 Jan;35(1):8-13 [18157061.001]
  • [Cites] J Clin Microbiol. 2008 May;46(5):1614-9 [18322062.001]
  • [Cites] Sex Transm Dis. 2008 Jul;35(7):649-55 [18461013.001]
  • [Cites] Sex Transm Dis. 2008 Nov;35(11 Suppl):S45-50 [18449069.001]
  • [Cites] Sex Transm Dis. 1999 Oct;26(9):548 [10534211.001]
  • [Cites] JAMA. 2000 Jul 26;284(4):443-6 [10904506.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):260-4 [11463925.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):758-61 [11880389.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4056-9 [12409374.001]
  • [Cites] MMWR Recomm Rep. 2002 Oct 18;51(RR-15):1-38; quiz CE1-4 [12418541.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):835-7 [12574295.001]
  • [Cites] Sex Transm Dis. 2003 Oct;30(10):769-73 [14520176.001]
  • [Cites] Sex Transm Infect. 2004 Feb;80(1):68-71 [14755041.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3300-2 [15243099.001]
  • [Cites] J Clin Microbiol. 2004 Oct;42(10):4749-58 [15472336.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1387-90 [15494917.001]
  • [Cites] J Infect Dis. 1994 Nov;170(5):1308-11 [7963734.001]
  • [Cites] J Clin Microbiol. 1994 Nov;32(11):2682-5 [7852556.001]
  • [Cites] J Clin Microbiol. 2005 Mar;43(3):1372-3 [15750110.001]
  • (PMID = 19386838.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI068613; United States / NIAID NIH HHS / AI / U01 AI068613-04; United States / NIAID NIH HHS / AI / UM1 AI068613; United States / NIAID NIH HHS / AI / AI068613-01
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2691063
  •  go-up   go-down


87. Boatsman EE, Fu CH, Song SX, Moore TB: Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J Pediatr Hematol Oncol; 2010 Mar;32(2):e57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation.
  • INTRODUCTION: Infant acute lymphoblastic leukemia (ALL) is considered a high-risk entity.
  • By morphology, infant ALL is classified as a lymphoid lineage leukemia; however, its physiologic behavior has brought many to consider it a pathologic hybrid between lymphoid leukemia and myeloid leukemias.
  • As such, standard of care currently employs the use of chemotherapeutic agents used commonly in ALL protocols and agents typically reserved for the treatment of myelogenous lineage leukemias.
  • The role of hematopoietic stem cell transplantation and graft-versus-leukemia effect in these patients has not been well studied.
  • CASE PRESENTATION: An earlier healthy 9-week-old Hispanic male diagnosed with precursor B-cell lymphoblastic leukemia was treated with protocol P9407 and matched sibling hematopoietic stem cell transplantation.
  • CONCLUSION: Traditionally, graft-versus-leukemia effect was thought to contribute therapeutically little to the treatment of ALL by hematopoietic stem cell transplantation (HSCT).
  • The effects of graft-versus-leukemia immunologic phenomenon in our patient with infant acute lymphoblastic leukemia underscore the potential that infant ALL may not be entirely the same biologic entity as standard pediatric ALL and may be more responsive than understood earlier.
  • Therapeutic response and appearance of GVHD after the withdrawal of immunosuppression in this patient provides evidence that graft-versus-leukemia effect may play a role in disease control in infant ALL after HSCT.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168246.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Vimaleswaran KS, Zhao JH, Wainwright NW, Surtees PG, Wareham NJ, Loos RJ: Association between serotonin 5-HT-2C receptor gene (HTR2C) polymorphisms and obesity- and mental health-related phenotypes in a large population-based cohort. Int J Obes (Lond); 2010 Jun;34(6):1028-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Studies have shown that common single-nucleotide polymorphisms (SNPs) in the serotonin 5-HT-2C receptor (HTR2C) are associated with antipsychotic agent-induced weight gain and the development of behavioural and psychological symptoms.
  • METHOD: Six tagSNPs, which capture all common genetic variation in the HTR2C gene, were genotyped in 4978 men and women from the European Prospective Investigation into Cancer (EPIC)-Norfolk study, an ongoing prospective population-based cohort study in the United Kingdom.
  • RESULTS: Of the six HTR2C SNPs, only the T allele of the -759C/T SNP showed borderline significant associations with higher body mass index (BMI) (0.23 kg m(-2); (95% confidence interval (CI): 0.01-0.44); P=0.051) and increased risk of lifetime major depressive disorder (MDD) (Odds ratio (OR): 1.13 (95% CI: 1.01-1.22), P=0.02).
  • CONCLUSIONS: Our findings suggest that common HTR2C gene variants are unlikely to have a major role in obesity- and mental health-related traits in the general population.
  • [MeSH-minor] Adult. Aged. Body Mass Index. Depressive Disorder / genetics. Female. Genetic Variation. Humans. Male. Middle Aged. Phenotype. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065966.001).
  • [ISSN] 1476-5497
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / MC/ U106179471; United Kingdom / Medical Research Council / / G9502233; United Kingdom / Cancer Research UK / / C865/A2883; United Kingdom / Medical Research Council / / G0300128; United Kingdom / Medical Research Council / / MC/ U106188470; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Receptor, Serotonin, 5-HT2C
  •  go-up   go-down


89. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol; 2006 Aug 15;98(4):525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
  • N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) is well established as a predictor of prognosis in patients with left ventricular dysfunction.
  • Although a similar prognostic significance has been suggested in 1 study of right ventricular failure and idiopathic pulmonary arterial hypertension, NT-pro-BNP has not been assessed as a marker of disease severity in a more heterogenous group of patients with chronic precapillary pulmonary hypertension (PH).
  • Hence, this study assessed plasma NT-pro-BNP and other clinical variables in 61 consecutively recruited patients with various forms of chronic precapillary PH.
  • Right-sided cardiac catheterization and cardiopulmonary exercise testing were performed at baseline, and the prognostic significance of NT-pro-BNP was investigated with a mean follow-up of 25 months.
  • Compared with age-matched controls (n = 10), plasma NT-pro-BNP was significantly greater in those with idiopathic pulmonary arterial hypertension (n = 16), chronic precapillary PH associated with other diseases (n = 26), and chronic thromboembolic disease (n = 19) and was correlated with hemodynamic variables and functional capacity.
  • In 17 medically treated patients, the significant decrease in NT-pro-BNP levels correlated with improved hemodynamics.
  • Baseline NT-pro-BNP was an independent predictor of mortality.
  • Kaplan-Meier survival analysis according to the median value of NT-pro-BNP (168 pmol/L) demonstrated a significantly higher mortality rate in those with supramedian values than in those with low plasma levels (p = 0.010).
  • In conclusion, these findings suggest that in a heterogenous group of patients with chronic precapillary PH, plasma NT-pro-BNP can be used to determine the clinical severity of disease and is independently associated with long-term mortality.

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893710.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


90. Pieters R: [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%]. Ned Tijdschr Geneeskd; 2010;154:A1577
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%].
  • [Transliterated title] Behandeling van acute lymfatische leukemie bij kinderen en adolescenten. Zijn we er bijna?
  • Acute lymphoblastic leukaemia (ALL) is the most prevalent type of cancer in patients under the age of 18 years.
  • Prognostically important factors are age at diagnosis, genetic abnormalities in the leukaemic cells and initial response to therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858304.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Tan TY, Tan AL, Tee NW, Ng LS: A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore; 2008 Oct;37(10):835-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Worldwide, Candida albicans is the most common Candida species implicated in bloodstream infections.
  • Fluconazole resistance is known to be more common in non-albicans species, but is also reported in C. albicans.
  • Isolates were identified by a common protocol, and antifungal susceptibility testing was performed by microbroth dilution (Sensititre One, Trek Diagnostics, United Kingdom).
  • RESULTS: The most common isolates were C. albicans (37%), C. tropicalis (27%) and C. glabrata (16%).
  • All C. albicans and C. parapsilosis were susceptible to fluconazole and voriconazole, while susceptibility to fluconazole was much more variable for C. glabrata and C. krusei.

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037517.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


92. Gibb H, Hilszczański J, Hjältén J, Danell K, Ball JP, Pettersson RB, Alinvi O: Responses of parasitoids to saproxylic hosts and habitat: a multi-scale study using experimental logs. Oecologia; 2008 Feb;155(1):63-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parasitoid wasps and beetle hosts were collected from nine locations, each containing three spruce-dominated stand types (clear-cut, mature managed and unmanaged stands), using emergence traps on experimental CWD.
  • We tested parasitoid responses to stand type, CWD volume, abundance of known and probable hosts and longitude.
  • Stand type appeared in best-fit models for all common species, suggesting that wasps respond strongly to habitat at local scales.
  • Host abundance appeared in best-fit models for three of five common species, proving significant only for Bracon obscurator, the abundance of which correlated with that of Orthotomicus laricis at both trap and site levels.
  • The role of habitat area at greater scales thus varied greatly amongst species, but our data suggest that dispersal of these common early successional species may not be strongly restricted at the current scale of fragmentation of their boreal habitats.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Biol Sci. 2005 Jan 22;272(1559):203-10 [15695212.001]
  • [Cites] Evolution. 1989 Jan;43(1):223-225 [28568501.001]
  • [Cites] Oecologia. 2000 Jan;122(1):129-137 [28307950.001]
  • [Cites] Oecologia. 1994 Feb;97(1):17-25 [28313585.001]
  • [Cites] Science. 2001 Aug 17;293(5533):1314-6 [11509730.001]
  • [Cites] Science. 1994 Jun 10;264(5165):1581-4 [17769603.001]
  • [Cites] Oecologia. 1999 Jul;120(1):92-101 [28308059.001]
  • [Cites] Proc Biol Sci. 2005 Nov 7;272(1578):2225-35 [16191634.001]
  • [Cites] Ambio. 2003 Dec;32(8):542-8 [15049351.001]
  • [Cites] Annu Rev Entomol. 2004;49:405-30 [14651470.001]
  • [Cites] J Chem Ecol. 2004 Apr;30(4):703-17 [15260218.001]
  • (PMID = 17972105.001).
  • [ISSN] 0029-8549
  • [Journal-full-title] Oecologia
  • [ISO-abbreviation] Oecologia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


93. Gandemer V, Rio AG, de Tayrac M, Sibut V, Mottier S, Ly Sunnaram B, Henry C, Monnier A, Berthou C, Le Gall E, Le Treut A, Schmitt C, Le Gall JY, Mosser J, Galibert MD: Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia. BMC Genomics; 2007;8:385
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia.
  • BACKGROUND: The t(12;21)(p13;q22) translocation is found in 20 to 25% of cases of childhood B-lineage acute lymphoblastic leukemia (B-ALL).
  • RESULTS: We compared the leukemia cell gene expression profiles of 16 TEL/AML1-positive ALL patients to those of 44 TEL/AML1-negative patients, whose blast cells did not contain any additional recurrent translocation.
  • Gene enrichment analysis defined five enriched GO categories: cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding, associated with 14 genes -RUNX1, TCFL5, TNFRSF7, CBFA2T3, CD9, SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7, SEMA6A, CTGF, LSP1, TFPI - highlighting the biology of the TEL/AML1 sub-group.
  • CONCLUSION: Gene expression analyses of leukemia cells from 60 children with TEL/AML1-positive and -negative B-lineage ALL led to the identification of five biological processes, associated with 14 validated genes characterizing and highlighting the biology of the TEL/AML1-positive ALL sub-group.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Profiling / methods. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1317-9 [17113638.001]
  • [Cites] Blood. 2001 Aug 1;98(3):558-64 [11468150.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):41-56 [11699220.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):417-20 [12124171.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3118-30 [12374679.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):155-64 [12526921.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1679-82 [12886264.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cancer Sci. 2003 Oct;94(10):841-6 [14556655.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2249-50 [14523475.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):35-42 [14630078.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 18;5:16 [14975175.001]
  • [Cites] BMC Genomics. 2004 Sep 23;5:71 [15387886.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):190-5 [9628428.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):26-35 [15982341.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1089-94 [16038737.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):21-9 [16157196.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):534-41 [16412629.001]
  • [Cites] Leukemia. 2006 Mar;20(3):410-6 [16424874.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • (PMID = 17956600.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  • [Other-IDs] NLM/ PMC2211320
  •  go-up   go-down


94. Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE: Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women &lt;or=55 years. Carcinogenesis; 2006 Nov;27(11):2209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 924T>C, 8360G>C and 30537G>C) to represent all common (>or=5%) haplotypes reported in the National Institute of Environmental Health Sciences database and to reconstruct haplotypes.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Cycle Proteins / genetics. Genetic Predisposition to Disease. Nuclear Proteins / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714331.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA108364; United States / NIEHS NIH HHS / ES / ES11740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


95. Koch AM, Rauh M, Zink S, Singer H: Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr; 2006 Jul;95(7):805-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age.
  • BACKGROUND: B-type natriuretic peptide (BNP) and the N-terminal fragment of proBNP (NT-proBNP) seem to be useful diagnostic tools also in children with cardiac disease.

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801175.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


96. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T: Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol; 2005 Mar;33(3):344-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
  • OBJECTIVE: Natural killer (NK) cell-mediated cytotoxicity contributes to the innate immune response against numerous malignancies, including leukemias.
  • Acute lymphoblastic leukemias (ALL) often display a high degree of resistance, the mechanisms of which have not been elucidated.
  • METHODS: We used the well-characterized NK cell line NK-92 as a model to investigate whether mechanisms commonly implicated in tumor escape from NK cell killing are relevant for ALL.
  • RESULTS: We demonstrate selective resistance of B-precursor ALL to NK-92 cytotoxicity even in the absence of inhibitory killer cell immunoglobulin-like receptors (KIR), except for KIR2DL4.
  • We also show that human leukocyte antigen-G, a ligand of KIR2DL4, expressed on a subset of ALL, does not mediate resistance of NK-cell mediated lysis.
  • In contrast the NK-sensitive T-ALL (MOLT-4) expressed moderate amounts of MHC class I chain-related gene AB (MICA/B) a ligand for the NK cell activating receptor NKG2D, while expression of MICA/B was absent in resistant B-ALL cell lines.
  • CONCLUSIONS: The NK cell-resistance of B-lineage ALLs does not appear to involve inhibitory mechanisms, but suggests deficient NK cell activation.
  • Thus, immunostrategies designed to enhance ALL sensitivity toward NK cell-mediated cytotoxicity should focus on mechanisms of NK cell activation.
  • [MeSH-major] Burkitt Lymphoma / immunology. Immunity, Cellular. Immunity, Innate. Killer Cells, Natural / immunology. Tumor Escape
  • [MeSH-minor] B-Lymphocytes. Cell Line, Tumor. Gene Expression Regulation, Leukemic / immunology. Histocompatibility Antigens Class I / immunology. Humans. Lymphocyte Function-Associated Antigen-1 / immunology. NK Cell Lectin-Like Receptor Subfamily K. Receptors, Immunologic / immunology. Receptors, KIR. Receptors, KIR2DL4. Receptors, Natural Killer Cell

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730858.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KIR2DL4 protein, human; 0 / KLRK1 protein, human; 0 / Lymphocyte Function-Associated Antigen-1; 0 / MHC class I-related chain A; 0 / MICB antigen; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR2DL4; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


97. Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, Griesmacher A, Guzman NA, Lindner HH: Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem; 2008 May;54(5):858-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The specific forms of pro-B-type natriuretic peptide (proBNP) that occur in human blood are not yet clear.
  • METHODS: For affinity chromatography, we coupled Fab' fragments of polyclonal sheep antibodies specific for N-terminal proBNP (NT-proBNP) epitope 1-21 to silica beads.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339696.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


98. Inoue Y, Tojo A, Sekine R, Soda Y, Kobayashi S, Nomura A, Izawa K, Kitamura T, Okubo T, Ohtomo K: In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging; 2006 May;33(5):557-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals.
  • We conducted cell culture studies to investigate the relationship between bioluminescent signal intensity and viable cell numbers in murine leukaemia model cells.
  • METHODS: Interleukin-3 (IL-3)-dependent murine pro-B cell line Ba/F3 was transduced with firefly luciferase to generate cells expressing luciferase stably under the control of a retroviral long terminal repeat.
  • The cells were cultured under various conditions, and bioluminescent signal intensity was compared with viable cell numbers and the cell cycle stage.
  • The bioluminescence intensities tended to reflect cell proliferation and responses to imatinib in cell culture studies.
  • However, the luminescence per viable cell was influenced by the IL-3 concentration in factor-dependent cells and by the stage of proliferation and imatinib concentration in factor-independent cells, thereby impairing the proportionality between viable cell number and bioluminescent signal intensity.
  • Luminescence per cell tended to vary in association with the fraction of proliferating cells.
  • CONCLUSION: Although in vivo bioluminescence imaging would allow non-invasive monitoring of leukaemia model animals, environmental factors and therapeutic interventions may cause some discrepancies between tumour burden and bioluminescence intensity.
  • [MeSH-major] Disease Models, Animal. Leukemia / diagnosis. Leukemia / therapy. Luminescent Measurements / methods. Microscopy, Fluorescence / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Cell Survival. Disease Progression. Luciferases. Luminescent Proteins. Mice. Prognosis. Reproducibility of Results. Sensitivity and Specificity